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"Was ist das Schwerste von allem? Was Dir das Leichteste dünket:  
Mit den Augen zu sehn, was vor den Augen dir lieget."  
 
J.W. von Goethe, Xenien aus dem Nachlass 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Tobias, Niklas and Sofia  
4 
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ABSTRACT 
The myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant 
bone marrow disorders characterized by peripheral cytopenia(s) and increased risk of 
progression to acute myeloid leukemia (AML). International Prognostic Scoring system 
(IPSS) Low- or Intermediate (INT)-1 risk MDS with a deletion of 5q (del5q) were 
considered to have an indolent course and a low risk for progression to AML as 
compared to other MDS subtypes. However, more recent studies have shown that 
overall survival (OS) and risk for AML progression vary greatly in del(5q) MDS 
patients indicating that factors beyond established risk scoring systems impact patient 
outcome. Molecular abnormalities have emerged as putative prognostic markers.  
We performed molecular studies in a patient with classical 5q- syndrome who 
unexpectedly evolved to high-risk MDS with complex karyotype (Paper I). 
Immunohistochemistry (IHC) of pre-treatment marrow biopsies revealed a small 
fraction of progenitors with strong p53 expression and sequencing confirmed a TP53 
mutation. TP53 mutated subclones had not been described in MDS with isolated 
del(5q) and indicated a previously unknown heterogeneity. In a subsequent study of 55 
patients with lower-risk del(5q) MDS, 18% of the patients were found to have TP53 
mutated subclones at diagnosis which rendered them at higher risk for progression 
(Paper II). Interestingly, the association with outcome was even stronger for p53 IHC 
indicating a high sensitivity of this method for early identification of patients with 
adverse outcome. As a next step, we assessed p53 protein expression in a cohort of 85 
lower-risk del(5q) MDS patients treated with lenalidomide within a clinical trial (Paper 
IV). P53 IHC positive patients showed significantly shorter overall survival, higher risk 
for leukemic transformation, and lower cytogenetic response rate to lenalidomide, 
hence validating the results from Paper II. Importantly, pyrosequencing analysis of 
microdissected IHC stained cells confirmed that cells with strong staining carried TP53 
mutations, while moderate staining reflected wild-type TP53.  
Due to the apparently exquisite sensitivity of the del(5q) clone to len, we hypothesized 
that higher doses of lenalidomide may induce cytogenetic and clinical responses also in 
patients with high-risk MDS/AML with chromosome 5 abnormalities who were 
refractory or ineligible for standard treatment (Paper III). In this study, we 
demonstrated that treatment was able to inhibit the del(5q) tumor clone in a cohort of 
patients with extremely advanced disease, which suggests that the selective inhibitory 
effect of len in vitro may be translated into a therapeutic response in vivo. 
Importantly, TP53 mutations were common (62%) in this cohort, and uniformly 
associated with treatment failure. Altogether, our findings suggest an important role 
of the p53 pathway in both low- and high-risk del(5q) MDS, and in relation to 
treatment with lenalidomide. These findings will have major implications for risk 
stratification and the choice of therapy. 
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1. ABBREVIATIONS 
 
AA 
ALIP 
ANC 
AML 
ALIP 
Aza 
BM 
CDR 
CMML 
CyR 
ELN 
EMA 
Se-EPO 
FCM 
FFPE BM 
G-CSF 
Hb  
HSC 
IHC 
IPSS 
IPSS-R 
RA 
Len 
LCM 
MDS 
MPN 
OS 
PB 
RAEB 
RARS 
RCMD 
RCMD-RS 
 
t-AML  
TP53 
WBC 
WHO 
WPSS 
Aplastic anemia 
Abnormal localization of immature precursors 
Absolute neutrophil count 
Acute myeloid leukemia 
Abnormal localization of immature precursors 
Azacytidine 
Bone marrow 
Commonly deleted region 
Chronic myelomonocytic leukemia 
Cytogenetic response 
European Leukemia Network 
European Medicines Agency 
Serum-Erythropoietin 
Flow cytometry 
Formalin-fixed paraffin-embedded bone marrow 
Granulocyte colony-stimulating factor 
Hemoglobin 
Hematopoietic Stem Cell 
Immunohistochemistry 
International Prognostic Scoring System 
Revised IPSS 
Refractory anemia 
Lenalidomide 
Laser cell microdissection 
Myelodysplastic syndrome 
Myeloproliferative neoplasm 
Overall survival 
Peripheral blood 
Refractory anemia with excess of blasts 
Refractory anemia with ringsideroblasts 
Refractory cytopenia with multilineage dysplasia 
Refractory cytopenia with multilineage dysplasia and 
ringsideroblasts 
Therapy-related AML 
Tumor protein p53 
White blood count 
World Health Organization 
WHO-based Prognostic Scoring System 
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2. THE MYELODYSPLASTIC SYNDROMES (MDS) 
 
2.1. Definition  
The myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal 
hematopoietic stem cell (HSC) disorders characterized by cytopenia(s), dysplasia in 
one or more of cell lineages, ineffective hematopoiesis, and increased risk of 
progression to acute myeloid leukemia (AML). MDS can arise de novo or as a 
consequence of previous chemotherapy or radiation. Although the majority of MDS are 
characterized by progressive bone marrow (BM) failure, the clinical course varies 
substantially in the different subtypes with survival ranging from a few months to 
decades (1). 
 
2.2. Epidemiology 
MDS is a disease of the elderly and one of the most common hematologic cancer in 
patients over the age of 70 years, among which the annual incidence exceeds 20 per 
100,000 persons (2). Since January 2009, all newly diagnosed cases of MDS in Sweden 
are registered in a national cancer registry as part of the INCA-platform 
(www.incanet.se). The number of registered MDS diagnoses was 265 patients for 2009 
and 309 patients for 2010 with a crude incidence of 4 cases/100.000 inhabitants/year. 
Thus, the incidence for this time period is in line with previous Swedish and 
international reports (3-5). However, there are indications that MDS may be 
underreported to cancer registries, in part due to the lack of formal diagnostic testing in 
this patient population (3, 6). In a recent regional Australian study the incidence was 
almost twofold higher as compared to data from central cancer registries in Australia 
(for 2007 9.6 per 100.000/year vs. 4.8 per 100.000/year). In two other studies using 
US Medicare data for patients ≥ 65 years up to 4-fold incidence rates for MDS were 
reported (3, 6) as compared to US cancer registry data with 3.3 per 100 000 persons/year 
during 2001-2004 and an estimated prevalence of 55 000 persons in the US (7). One 
possible explanation for the discrepancy could be due to the way MDS was 
registered. For example, it was found that many cases were linked to individuals 
already registered for another cancer, and existing guidelines recommended the 
removal of MDS as a separate primary tumor (3). The incidence of MDS may also be 
underreported because of failure to recognize the diagnosis. For example, given the 
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chronic nature of disease, a possible MDS patient may be asymptomatic or 
incompletely investigated and diagnosed as unspecified anemia. 
The median age at diagnosis in the INCA cohort was 75 years (range, 17-94 years) and 
70% of the patients were >70 years old. There was a slight male predominance (56%). 
MDS was related to previous cytostatic treatment or radiotherapy in 10% of the cases.  
Risk factors for MDS include cytostatic treatment and in particular alkylating agents, 
radiation therapy, and to a lesser extent, tobacco use and occupational exposure to 
solvents and agricultural chemicals (8). The risk of MDS is markedly increased in 
certain genetic syndromes and in context of inherited bone marrow failure syndromes 
(i.e. Fanconi anemia, Shwachman-Diamond syndrome, severe congenital neutropenia, 
Dyskeratosis congenita, Diamond-Blackfan anemia). 
 
2.3 Clinical and morphological diagnosis  
Diagnostic work-up of MDS is well described in the Nordic guidelines for MDS 
(www.nmds.org) and includes detailed clinical information with family history, 
relevant laboratory data, cytomorphologic evaluation of peripheral blood and bone 
marrow aspirate smear, bone marrow biopsy, cytogenetic analysis, and molecular 
analysis, if relevant. Using this integrated approach, an MDS diagnosis can be made in 
most cases and non-malignant causes of cytopenia can be excluded.  
However, the standard diagnostic criteria for MDS and its various subtypes using the 
World Health Organization (WHO) classification rely heavily on the (subjective) 
morphologic evaluation of bone marrow cells. In spite of recent advances in the 
understanding of the pathogenesis of the disease, these disorders remain among the 
most challenging of the myeloid neoplasms in terms of proper diagnosis and 
classification (9, 10). 
 
2.3.1. Clinical features 
MDS patients typically present with symptoms related to persistent (>6 months) 
refractory cytopenia: more than 80% of patients have anemia, 40% neutropenia and 30-
40% thrombocytopenia. The thresholds for cytopenias as recommended in the 
International Prognostic Scoring System (IPSS) for risk stratification in MDS are 
hemoglobin of <10g/dl, absolute neutrophil count (ANC) <1.8x109/L and platelets 
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<100x109/L. However, levels above these thresholds do not exclude the diagnosis of 
MDS if definitive morphological and cytogenetic findings are present. Macrocytosis is 
a common laboratory finding and may be an early sign even without associated anemia. 
Significant cytopenia is associated with higher morbidity and mortality in MDS (11). 
 
2.3.2. Cytological features 
The morphological classification of MDS is based on the percentage of blasts in the 
BM and PB, the degree of dysplasia and the number of dysplastic cell lineages as well 
as the presence of ring sideroblasts (12). Minimal diagnostic criteria for MDS have been 
proposed (Table 1) which allow discrimination of MDS from other neoplastic or 
reactive disorders associated with cytopenia and/or dysplasia (13, 14). In patients who do 
not fulfill these minimal criteria, a provisional diagnosis of idiopathic cytopenia or 
dysplasia of undetermined significance/uncertain significance (ICUS/IDUS) may be 
considered (15-17). 
 
Table 1. Minimal diagnostic criteria for MDS (adapted from Valent et al., 2009) 
Criteria Major (diagnostic) test 
Prerequisite criteria (both must be 
fulfilled) 
• Constant cytopenia 
• Exclusion of other diseases as primary 
cause of cytopenia/ dysplasia 
 
 
Blood counts (over 6 months) 
BM smear and histology, cytogenetics, 
FCM, molecular markers, other relevant 
investigations* 
MDS-related criteria (one of these must be 
fulfilled) 
• Morphological dysplasia in one of the 
three myeloid cell lineages 
• Blast cell count ≥5% 
 
 
• Ring sideroblasts ≥15% 
• Typical karyotype anomaly 
 
 
BM and PB smear, in certain situations: 
BM histology 
BM smear and BM histology, 
cytogenetics, FCM, molecular markers, 
other relevant investigations* 
Iron stain 
Conventional karyotyping and FISH 
Co-criteria 
• BM stem cell function 
• Abnormal immunophenotype  
• Monoclonality of myeloid cells 
• Abnormal gene expression profile 
 
Circulating CFC, reticulocytes 
Flow cytometry, Immunohistochemistry 
Molecular markers, mutations 
mRNA profiling assays 
*Investigations depend on the case history and overall situation and should include a 
complete chemistry profile with inflammation parameters, immunoglobulins, S-EPO level, 
S-tryptase level. FCM, flow cytometry; CFC, colony-forming progenitor cells 
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The cytopenias may correspond to the dysplastic cell lineage, however, in a recent 
study including 2032 MDS patients from the Düsseldorf Registry, no association 
between the type of cytopenia and dysplasia was found (18). In addition, patients with 
borderline features may have normal peripheral blood status. The recommended 
requisite percentage of cells with dysplasia is ≥10% for each cell lineage; megakaryo-
cytic dysplasia should be assessed on at least 30 megakaryocytes in smears or bone 
marrow sections. 
 
Figure 1. Morphological features of dysplasia 
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryocytopoiesis 
Nuclear 
Nuclear budding 
Hyperlobation 
Internuclear bridging 
Karyorrhexis 
Multinuclearity 
Megaloblastic changes 
 
Cytoplasmatic 
Ring sideroblasts 
Vacuolization 
Periodic acid-Schiff 
positivity 
Small or unusual large size 
Nuclear hypolobation  
(pseudo Pelger Huët; 
pelgeroid) 
Irregular hypersegmentation 
Decreased granules 
Agranularity 
Pseudo Chediak-Higashi 
granules 
Auer rods 
Micromegakaryocytes 
Nuclear hypolobation 
Multinucleation 
 
        
 
The enumeration of blasts in bone marrow aspirate and peripheral blood smear is 
essential in the diagnostic work up, and for the classification and prognostication of 
MDS. To determine the blast percentage in the BM, a 500-cell differential of all 
nucleated cells in a smear or trephine imprint is recommended and in the PB, a 200-
leukocyte differential. Assessment of blast percentage and degree of dysplasia can be 
problematic, especially when samples are hemodiluted or when the quality of the 
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smear is ‘suboptimal’. In addition, smears may be hypocellular in hypoplastic or 
fibrotic BM, not allowing an adequate quantitative and qualitative assessment. 
Overall, the necessity of high quality slide preparations cannot be overemphasized, and 
results should always be correlated to the histological assessment. Also, differential 
counts should not be substituted with the enumeration of blasts by flow cytometry since 
the difference in sample quality and sample processing may lead to over- or 
underestimation of blast percentage by flow cytometry.  
 
2.3.3. Histology and Immunohistochemistry  
The histological and immunohistochemical examination of BM biopsies contributes 
essentially to the diagnosis, classification and prognostication of suspected MDS (19, 20). 
Standards and guidelines in the evaluation of MDS by histology and IHC have recently 
been proposed by a consortium of US and EU experts at a Working Conference (21). 
The biopsy allows for precise assessment of marrow cellularity, fibrosis and architectu-
ral features (Figure 2). BM cellularity and grade of fibrosis should be assessed 
according to the European Consensus Grading System (22). The presence of marrow 
fibrosis has been identified as independent prognostic risk factor in several studies (23-
26). Significant myelofibrosis (grade 2-3) is observed in approximately 10% of MDS 
and often associated with multilineage dysplasia, high transfusion requirement, and 
poor prognosis. The biopsy helps to distinguish hypoplastic MDS from aplastic anemia 
or hypoplastic AML (20), however, several biopsies may be required before a final 
diagnosis can be made. Moreover, it is clinically relevant to distinguish hypoplastic 
from normo- or hyperplastic and fibrotic MDS, since treatment approaches may differ. 
In addition, histology may reveal an unrelated or co-existing hematopoietic neoplasm. 
 
 
 
 
 
 
 
Figure 2. BM histology in a patient with MDS shows megakaryocytic hyperplasia, dysplasia 
and fibrosis (Hematoxylin-eosin and Gomori Silver stain, 40x objective).   
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Immunohistochemistry has been proposed in patients with (suspected) MDS (15, 19, 27) 
using a minimal IHC panel; additional (lineage-specific) markers may be used when 
the diagnosis MDS is in question or another co-existing neoplasm is suspected (21). 
The CD34 stain is useful for the enumeration of CD34+ blasts in the biopsy, and also 
for the detection of CD34+ clusters which has been suggested as an independent 
prognostic marker in MDS (24, 28, 29). In situations where blast cells are CD34-negative, 
CD117/KIT has been recommended as an additional marker (21). However, since 
CD117/KIT is also expressed by a proportion of proerythroblasts (30) evaluation may 
be difficult in some cases. There is generally good correlation between the percentage 
of myeloblasts as determined by cytology and histology, however, discordant results 
may be seen both with and without the presence of marrow fibrosis. In addition, the 
CD34 antigen may be detectable in immature megakaryocytes and megakaryoblasts in 
MDS (Figure 3), and increased CD34 expression has been associated with advanced 
disease (31). However, CD34-expression is not a specific feature of MDS- 
megakaryocytes.  
 
 
Figure 3. IHC demonstrates an increase in CD34+ blast cells, aberrant expression of 
CD34 in megakaryocytes and microvascular hyperplasia. A fraction of BM progenitor 
cells shows strong p53 staining (brown nuclei; right plot).  
 
 
2.3.4. WHO Classification 
The World Health Organization (WHO) classification of MDS was updated in 2008 
and provides at date the best diagnostic approach to MDS (Table 2)(12). The WHO 
classification has considerable prognostic relevance (32), and its implementation into 
clinical practice is mandatory for optimal management of MDS. 
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Table 2. WHO 2008 Classification of Myelodysplastic Syndromes (ref. 12) 
WHO subtype Peripheral blood  Bone marrow findings 
Refractory cytopenias with 
unilineage dysplasia (RCUD) 
  Refractory anemia (RA) 
  Refractory neutropenia (RN) 
  Refractory thrombocytopenia RT) 
Unicytopenia or 
bicytopenia*  
No or rare blasts 
(<1%) ** 
  
Unilineage dysplasia: ≥10% 
of the cells in one linage 
<5% blasts 
<15% of erythroid precursors 
are ring sideroblasts 
Refractory anemia with ring 
sideroblasts (RARS) 
Anemia, no blasts ≥15% of erythroid precursors 
are ring sideroblasts,  
Erythroid dysplasia only  
<5% blasts 
Refractory cytopenia with 
multilineage dysplasia (RCMD) 
Cytopenia(s)                                 
No ore rare blasts 
(<1%) 
No Auer rods                                             
<1x10/L monocytes 
Dysplasia in ≥10% of the 
cells in ≥ 2 myeloid lineages 
<5% blasts in BM 
No Auer rods, +/- 15% ring 
sideroblasts 
Refractory anemia with excess 
blasts-1 (RAEB-1) 
  
  
Cytopenia(s),  
<5% blasts,  
no Auer rods 
<1x10/L monocytes 
Unilineage or multilineage 
dysplasia 
5-9% blasts** 
No Auer rods  
Refractory anemia with excess 
blasts-2 (RAEB-2) 
  
  
Cytopenia(s) 
<5% blasts 
Auer rods +/-*** 
<1x10/L monocytes 
Unilineage or multilineage 
dysplasia 
10-19% blasts 
Auer rods +/-  
Myelodysplastic syndrome-
unclassified (MDS-U) 
  
  
  
Cytopenia(s)                                                                  
 
≤1% blasts** 
  
  
  
Unequivocal dysplasia in
<10% of cells in ≥1 cell lines 
accompanied by a cyto-
genetic abnormality; 
considered as presumptive 
evidence for MDS, <5% 
blasts 
MDS associated with isolated 
del(5q) 
Anemia; usually                 
normal or increased 
platelet count                 
No or rare blasts 
(<1%) 
Normal to increased mega-
karyocytes with hypolobated 
nuclei; <5% blasts                                             
Isolated del(5q) abnormality                     
No Auer rods 
*Bicytopenia may occassionally be observed. Cases with pancytopenia should be 
classified as MDS-U; **If the marrow blast percentage is <5% but there are 2-4% 
myeloblasts in the blood, the diagnostic classification is RAEB 1. Cases of RCUD and 
RCMD with 1% myeloblasts in the blood should be classified as MDS-U; ***Cases with 
Auer rods and <5% myeloblasts in the blood and <10% in the bone marrow should be 
classified as RAEB-2 
 
However, the WHO 2008 classification was critically reassessed in a recent study based 
on a large number of patients with prolonged follow-up from the Düsseldorf MDS 
Registry, which led to the proposal of various modifications (18). For example, the 
separation of RCUD into RA, RT and RN was found to be of questionable value due 
to the difficulties of separating these three subcategories on the basis of hematological 
and/or morphological characteristics, but also due to the fact that they were similar in 
terms of prognosis. The same was found for RCMD and MDS-unclassified. 
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Therefore, a simplified classification for MDS without excess of blasts was proposed 
including the consolidation of RA, RT and RN into RCUD and the elimination of 
MDS-unclassified as a distinct subcategory.  
The “5q- syndrome” is the only subtype of MDS, which is defined by cytogenetics in 
addition to specific pathogenetic and morphologic characteristics. However, given its 
heterogeneous clinical course, it has become questionable whether it really represents a 
single true subcategory of MDS. The "5q- syndrome" is further discussed in section 
2.5. In addition, it is possible that multilineage dysplasia, a morphological parameter 
that is important from a prognostic point of view, can be better defined using molecular 
criteria. A recent study found that MDS patients with RARS, RCMD and RCMD-RS 
subtypes displayed comparable clinical and cytogenetic profiles (33). Yet, cytogenetics 
enabled a differentiated risk stratification within these morphologically defined “good-
risk” subtypes. It is likely that molecular makers may become an important part of 
future classification systems within the frame of the WHO classification.  
 
2.3.5. Cytogenetics 
Cytogenetic abnormalities are major determinants in the pathogenesis, diagnosis, and 
prognosis of MDS and have major impact on therapeutic decision-making in individual 
patients (34-36). Chromosomal abnormalities are detected in approximately 50% of 
patients with de novo MDS (Figure 4) and in up to 80% in therapy-related MDS (37-40). 
Aberrations are most common in the RAEB-subtypes.  
In MDS, unbalanced chromosomal abnormalities reflecting gain or loss of 
chromosomal material are more prevalent in comparison to AML, while balanced 
translocation are rare (38). The most frequently observed chromosomal abnormality in 
de novo MDS is the interstitial deletion of the long arm of chromosome 5, with or 
without additional karyotypic abnormalities (37, 38, 41).  
Certain cytogenetic abnormalities in MDS patients are associated with a characteristic 
morphology and clinical phenotype: the “5q- syndrome” is associated with the presence 
of hypolobated megakaryocytes and the del(17p) has been associated with the presence 
of Pseudo-pelger cells containing small vacuoles, a deletion of TP53 and a high risk of 
leukemic transformation (42). 
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Figure 4. Common chromosomal abnormalities in MDS including International Prognostic 
Scoring System predictions. Reprinted by permission from Nature Publishing Group.  
(Raza et al, Nature Reviews Cancer 2012, 12: 849-59) 
 
Recently, a new and comprehensive cytogenetic scoring system based on an 
international data collection of 2,902 patients was proposed (40). Schanz et al. defined 
19 cytogenetic categories, providing clear prognostic classification in 91% of all 
patients (Figure 5). The abnormalities were classified into five prognostic subgroups: 
very good, good, intermediate, poor, and very poor (>3 abnormalities). In addition, a 
number of new single abnormalities (inv(3)/t(3q)/del(3q), +8, del(11q), del(12p), 
i(17)(q10), +19, and +21) were newly integrated into the scoring system.  
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Figure 5. New cytogenetic classification of MDS (adapted from Schanz et al., 2011).   
 
The study revealed that deletion of chromosome 7 (del(7q) was more favorable than 
monosomy 7 with regard to OS and AML risk, a finding that had also been described 
in previous studies (43, 44). Consequently, deletion of 7q was classified as intermediate, 
whereas the loss of the whole chromosome 7 was associated with worse prognosis. 
The data from this large study contributed to the update of the revised IPSS (45) by 
refining the cytogenetic risk categories as presented in the following section.  
 
2.3.6. Prognosis, risk assessment and follow-up 
The natural history of MDS varies considerably; while some patients experience an 
indolent course, others show short overall survival and rapid transformation to AML. 
Therefore, risk stratification is critical for both prognostic assessment and formulating 
treatment goals. Several prognostic scoring systems have been developed to identify 
MDS subtypes with different outcomes and to stratify patients into lower and higher 
risk subgroups. These schemes are based on morphology and clinical variables such as 
cytopenias and cytogenetics. The most commonly used prognostic tool is the 
International Prognostic Scoring System (IPSS) from 1997 (46). The original IPSS was 
recently revised. The updated IPSS-R uses five instead of three cytogenetic prognostic 
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subgroups, splits marrow blast percentage <5% into two groups, and introduces more 
levels of cytopenia (Table 3) (45). However, the distinction of blast percentages between 
<2%, ≥2%-<5%, and ≥5% is critical in terms of reproducibility and needs to be 
validated. Interestingly, fibrosis was not confirmed as an independent prognostic 
marker in the IPSS-R, which could partly be due to the low frequency of samples that 
were assessed but it may also reflect differences in methodology. 
 
Table 3. Revised IPSS (adapted from Greenberg et al., Blood 120, 2012) 
Prognostic variable 0.0 0.5 1.0 1.5 2.0 3.0 4.0 
Cytogenetics 
BM blasts, % 
Hemoglobin (g/dl) 
Platelets (x10/L) 
ANC (x10/L) 
Very good 
≤2% 
≥10 
≥100 
≥0.8 
 
 
 
50-<100 
<0.8 
Good 
>2-<5% 
8-<10 
<50 
 
 
<8 
INT 
5-10% 
Poor 
>10% 
Very 
poor 
Risk category Risk score 
Very low ≤1.5 Prognostic subgroups:  
Very good: del(5q), -Y 
Good: normal,del(5q), del(12p), del(20q), double including 
del(5q) 
Poor: Inv(3)/t(3q)/del(3q), double including -7/del(7q),  
Complex karyotype: 3 abnormalities, -7 
Very poor: complex karyotype (>3 abnormalities) 
Low >1.5-3 
Intermediate >3-4.5 
High >4.5-6 
Very high >6 
 
The WHO classification-based prognostic system (WPSS) is a modification of the IPSS 
and includes multilineage dysplasia and transfusion dependency as additional adverse 
prognostic variables (47). Although the prognostic value of the latter has been validated 
in several studies (6, 48), it has been considered to be too subjective (49). In the refined 
WPSS model, severe anemia defined as hemoglobin levels lower than 9 g/dl in males 
and 8 g/dl in females, was found to be as effective as transfusion-dependency in the 
prognostic assessment (50). Finally, somatic mutations have emerged as fundamental 
determinants for outcome in MDS, it is likely that some of these in the future may be 
incorporated into existing models. 
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2.3.7. Flow cytometry – detection of aberrant patterns beyond the 
microscope 
Flow cytometry (FCM) has been recognized as additional tool in the diagnosis and 
prognosis of MDS. The current WHO 2008 classification recognizes multiple flow 
cytometric aberrancies (>3) in maturation patterns as indicative of MDS.  
FCM allows the identification of specific aberrations on both immature and mature 
compartments in the different hematopoietic lineages (51-53). Different groups have 
designed scoring systems for the diagnosis and prognosis of MDS (52, 54-60). However, so 
far, the only validated prognostic flow score is the FC scoring system designed by 
Wells et al. (61). In addition, validation of current assays and agreement on the 
techniques are prerequisites for its widespread acceptance and application in clinical 
practice. Therefore, the European Leukemia Network (ELN) working group was 
initiated to discuss and propose standards for FCM in MDS and to define minimal FC 
parameters to enable the categorization of FCM results as “normal”, “suggestive of”, or 
“diagnostic of” MDS (51, 62). Further studies have been initiated by this working group 
for the establishment of diagnostic and prognostic FC panels in MDS.  Recently, a 
multicenter validation confirmed the ability to distinguish low risk MDS without other 
specific markers (i.e. cytogenetics and ring sideroblasts) from non-clonal cytopenias 
(52). These findings were confirmed in a previous study, which demonstrated the utility 
of a FCM-score for the detection of marrow dysplasia based on four highly 
reproducible parameters (63). However, it should be stressed that FCM should only be 
used as part of an integrated diagnosis in MDS.    
 
2.4. Pathogenesis 
2.4.1. A stem cell disease 
The MDS clone has its origin in the hematopoietic stem cell compartment. Previous 
studies using transgenic MDS mouse models demonstrated that MDS HSCs can be 
transplanted to recipient mice who displayed all of the critical features of MDS, 
including peripheral blood cytopenias, dysplasia and transformation to AML(64-66). 
Fluorescence in situ hybridization (FISH) and gene expression data from purified 
HSCs from 5q- MDS patients have suggested a hematopoietic stem cell origin for 
MDS (67-71). 
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In a recent study, Tehranchi et al identified rare and phenotypically distinct MDS stem 
cells in patients with del(5q) MDS (69). These MDS stem cells were selectively resistant 
to therapeutic targeting by lenalidomide at the time of complete clinical and cytogenetic 
remission, indicating their importance not only in the pathogenesis of MDS but also for 
treatment. Moreover, it was found that a large fraction of these stem cells were in the 
G0 phase of the cell-cycle and quantitative gene-expression analysis demonstrated 
increased expression of the cyclin-dependent kinase inibitor1C (CDKN1c) gene 
(p57KIP2) which has been implicated in stem-cell quiescence (72). In addition, the 
expression of several genes (HOXa9, MEIS1, MCL1, BMI1, and MycN) linked to 
stem-cell function and leukemic transformation was up-regulated in the stem cells (73-
76). Will et al. demonstrate that stem and progenitor cells in MDS are characterized by 
stage-specific expansion and contain epigenetic and genetic alterations (70). Moreover, 
longitudinal analysis in a patient treated with 5-azacytidine revealed that 
karyotypically abnormal HSCs persist even during complete morphologic remission 
and that expansion of clonotypic HSCs precedes clinical relapse. By transplanting 
purified human HSCs from MDS samples into immunodeficient mice, Pang et al 
provided direct evidence that HSCs are the disease-initiating cells in MDS (77). 
Additionally, MDS bone marrow samples harboring a clonal cytogenetic marker, 
contained immunophenotypic HSCs that were composed almost entirely of the MDS 
clone suggesting that MDS HSCs are expanding at the expense of normal HSC.  
Recent studies have linked p53 to the process of stem cell self-renewal (78-83), and 
suppression of p53 or the p53 pathway enhanced the production of pluripotent stem 
cells, suggesting that p53 limits the reprogramming of differentiated cells into a self-
renewing state (84-86).  The role of the TP53 pathway in MDS is discussed in detail in 
section 4.  
 
2.4.2. Gene mutations 
MDS consists of several molecularly distinct entities. Gene expression studies of 
progenitor cells from patients with MDS have underlined the heterogeneity of the 
disease at the molecular level (87-89), including difference in gene expression between 
low-risk and high-risk disease (88, 90), and between specific cytogenetic subcategories (91, 
92). The compendium of genes carrying recurrent somatic mutations in MDS has grown 
dramatically over the last few years with the application of single nucleotide 
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polymorphism (SNP) arrays, whole exome and genome sequencing.  Over 70% of 
MDS patients harbor somatic mutations or clonal cytogenetic abnormalities, and more 
than 50% of MDS patients carry at least one somatic mutation (93). The genes mutated 
in MDS can be grouped into several categories: transcription factors (e.g., TP53, 
RUNX1, ETV6, WT1) (94-99), epigenetic regulators and chromatin remodeling factors 
(e.g. TET2, DNMT3A, ASXL1, IDH1/2, EXH2) (100-110), pre-mRNA splicing factors 
(U2AF35, ZRSR2, SRSF2, SF3B1) (111-116), and signaling molecules (NRAS, JAK2, 
NPM1) (94, 117) (118-121). Table 4 lists frequently found molecular aberrations in de novo 
MDS and their suggested role in MDS progression.  
A recent work studied the clinical impact of point mutations in a cohort of 439 patients 
with MDS (94). Somatic mutations of TP53, EZH2, ETV6, RUNX1, and ASXL1 were 
found to be independent predictors of decreased survival and to improve the risk 
stratification provided by the IPSS. The phenotypic heterogeneity within MDS is likely 
to be driven by these genetic changes and their interaction with therapeutic options. The 
identification of somatic mutations may aid in diagnosis and follow-up of MDS (98). 
Therefore, testing for the presence of some of these mutations in PB or BM using deep 
sequencing is likely to become a clinical routine in the future. 
A next-generation sequencing study recently addressed and characterized parts of the 
clonal architecture in MDS, and subsequent progression to secondary AML (122). More 
than 90% of BM cells carried clonal somatic mutations at the time of MDS diagnosis, 
even in subtypes without excess of blasts. The percentage of cells with somatic 
mutations did not increase significantly with progression from MDS to AML, but the 
dominant clone did. These results indicate that clonal hematopoiesis is present at an 
early stage of the disease. In addition, it was found that the dominant secondary-AML 
clone was derived from a MDS founding clone in all cases, suggesting that therapies 
targeting these early mutations might be the most effective strategy for eliminating 
disease-propagating cells and improving the rate of response to chemotherapy for 
patients with secondary AML (123, 124). 
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Table 4. Common gene mutations in MDS 
Gene Chromo-some Frequency 
Prognostic 
impact Protein function Ref 
Oncogenes and tumor suppressor genes  
RUNX1 21q22 15% Poor Transcription factor 
important in 
hematopoiesis 
95,97, 99 
TP53 17p13 5-10% Poor Tumor suppressor gene See 
appendix 
NRAS 1p13.2 7-20% variable GTPase, oncogene when 
mutated 94, 121 
KRAS 12p12.1 2-5% Poor GTPase, oncogene when 
mutated 121 
ETV6 12p13.2 2-5% Poor Transcription factor 
important in 
hematopoiesis 
104 
EVI1 3q26 1-2% Poor Transcriptional regulator 
and oncoprotein involved 
in hematopoiesis and 
apoptosis 
104 
WT1 11p13  Poor  98 
Methylation of CpG islands  
TET2 4q24 20% unclear Methylation of CpG 
islands; methylcytosine 
required for 
myelopoiesis 
100,101,
105,106 
IDH1/2 2q33.3 and 
15q26.1 
5-10% unknown regulates TET2 activity 107-110 
DNMT3A 2p23.2 5-10% Poor DNA methyltransferase 102,111 
Histone modification  
ASXL1 20q11.1 10-15% Poor Histone binding protein 103 
EZ2H 7q36.1 5% Poor Histone 
methyltransferase 
 
112 
Spliceosome  
SF3B1 2q33.1 20% in MDS; 
65% in MDS-
RS 
variable spliceosome protein  115,116,
113 
U2AF1 21q22.3 not known None spliceosome protein  118 
ZRSR2 Xp22.1 not known None splideosome protein  114,115 
Others  
JAK2 9p24.1 50% in 
RARS-T 
unknown Protein tyrosine kinase    
CBL 11q23.3 2-5% unknown E3 ubiquitin ligase; 
negative regulator of 
transduction in 
haematopoietic cells 
  
RPS14 5q33.1 5q- syndrome unknown Ribosomal protein of the 
40S subunit   
AML-1/ 
RUNX1 
21q22  Poor Transcription factor, 
regulates differentiation 
of hematopoietic cells 
95,97,99 
NPM-1 5q35 
 
unknown 
Cell growth and 
proliferation, genomic 
stability 
122,123 
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2.4.3. Epigenetics 
Epigenetic alterations have profound effects on gene expression and may cause tumor 
suppressor gene silencing (reviewed in (125) ). Hypermethylation of genes involved in 
cell cycle control and apoptosis is commonly observed in MDS progenitors, in 
particular in high-risk disease (126). Important genes for cell cycle regulation are the 
cyclin-dependent kinase inhibitors p15 (INK4b) and p16 (INK4b). These two genes are 
rarely mutated or deleted, but transcription of the p15 gene is often silenced owing to 
abnormal methylation of its promoter region, and several studies indicate that 
approximately 50% of MDS show this alteration (127, 128). 
In contrast to changes in DNA sequence, silencing of genes by DNA methylation is a 
reversible process, and the introduction of demethylating agents (e.g. azacitidine and 
decitabline) in the treatment of high-risk MDS, have yielded encouraging results (129, 
130). Moreover, both drugs have shown to slow the progression of MDS to AML, which 
underlines the suggested role of hypermethylation in the progression of MDS into 
AML (131-133). 
Given the success of these DNA methyltransferase inhibitors in the treatment of MDS, 
multiple studies have been undertaken to better define the epigenetic landscape of MDS 
(125, 133-135). However, it is still unclear whether abnormal methylation pattern are driven 
by somatic mutations that alter the epigenetic state (such as DNMT3A, IDH1/2 and 
TET2 mutations), or whether epigenetic abnormalities per se are primary drivers of the 
disease. 
 
2.4.4. The role of the immune system 
Clinical and laboratory studies suggest that BM failure in MDS may, at least in part, be 
immune-mediated (136-138). Improvement of hematopoiesis has been seen following 
treatment with immunosuppressive regimens including anti-thymocyte globulin (ATG) 
and cyclosporine (139-144). Immunosuppressive therapy appears to be most effective 
early in the disease course of WHO RA/RCMD (145). Suggested immune-mediated 
mechanism include targeting of BM precursors by cytotoxic T lymphocytes or natural 
killer (NK) cells (136, 146), defects in immune tolerance (147), and the presence of a pro-
inflammatory microenvironment in the BM (148). 
T cells are thought to play an important role in BM failure in MDS. Recent research 
suggests that T regulatory cells (Tregs) are involved in the negative control of the 
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immune response which could promote the immune-mediated damage of normal BM 
precursors (149, 150). The role of T cells in the process of BM failure may be deducted 
from the therapy response seen to immunosuppressive agents which mainly target 
activated T cells (139, 151, 152). Furthermore, the expression of apoptotic molecules and the 
activation of enzymes involved in apoptosis was shown to be increased in MDS T cells 
(153). Other studies have reported on an increase in the number of cytotoxic T cells (137), 
whereas the function of NK cells was found to be significantly reduced in patients with 
high-risk MDS (154). Moreover, numerical and functional alterations of blood dendritic 
cells have been described in MDS (155-157). Recently, we showed that bone marrow 
dendritic cells (DC) were markedly reduced in all subtypes of MDS in comparison to a 
control group, indicating that the DC compartment may be involved in the 
pathobiology of MDS (158). Taken together, T-cell and NK-cell defects, decreased 
functional abilities of neutrophils and antigen-presenting cells, altered antibody and 
cytokine production appear to play a role in the pathophysiology of MDS.  
 
2.4.5. The bone marrow microenvironment – a disease driver in human 
MDS? 
Disruption of the BM microarchitecture is a common finding in MDS encompassing 
altered localization of hematopoietic cells within the BM (“topography”) and 
alterations in components that comprise the microenvironment. All hematopoietic 
lineages in MDS may be affected, including megakaryocytopoiesis (i.e. clusters of 
micromegakaryocytes, paratrabecular localization), granulopoiesis (i.e. clusters of 
immature precursors, “ALIPs”) and erythropoiesis (expansion or severe reduction). 
Alterations of the microenvironment include edema, fibrosis, vascular proliferation (159), 
lymphoid aggregates and inflammatory changes. These findings indicate that MDS is 
not only a disease of hematopoietic cells but also of the tissue. However, whether these 
BM stromal changes are an epiphenomenon or a pathogenetically important element of 
the disease itself remains unclear.  It appears that the proliferative advantage and the 
progressive nature of MDS involve the interaction of hematopoietic stem cells (HSC) 
with their microenvironment. In human MDS, xenotransplant models using 
immunodeficient mice have consistently shown poor engraftment of myelodysplastic 
cells and failure to confer the clinical hematopoietic phenotype of human MDS (66, 160). 
These observations have sparked the debate about a potentially causative or permissive 
role of the microenvironment and the question in how far components of the HSC niche 
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are implicated in MDS (161-166). Several groups have reported that abnormalities in 
stromal cells can induce MDS (or AML) in otherwise normal bone marrow cells (167-
170). Moreover, it was shown that dysfunction of bone progenitor cells can initiate 
myelodysplasia and leukemia predisposition in mice (167). Taken together, data from 
different animal models have suggested that cells within the BM microenvironment 
may have importance for the behaviour of HSC, regulating their maintenance, 
quiescence, self-renewal and differentiation. On the basis of these studies, a “niche-
based” model of leukemogenesis in MDS has been proposed (170). 
 
2.5. The “5q- syndrome” 
The ”5q- syndrome” refers to a unique subtype of MDS and was first described by Van 
den Berghe et al in 1974 who reported five patients with macrocytic anemia, normal 
to elevated platelet count, dyserythropoiesis, hypolobulated megakaryocytes and an 
interstitial deletion of the long arm of chromosome 5 (171). 
The presence of del(5q), either in isolation or in combination with additional 
cytogenetic aberrations, is the most frequently reported cytogenetic abnormality in 
MDS and is described in up to 15% of cases (38, 172) , while the incidence of the 5q- 
syndrome is much lower (173). In comparison to other subtypes of MDS, the 5q- 
syndrome is characterized by isolated del(5q), <5% BM blasts, female preponderance 
and a favorable prognosis with low risk of leukemic transformation. Indeed, the 
WHO classification of MDS identified the 5q- syndrome as a distinct clinical entity 
owing to its characteristic clinical and morphological features.  
 
 
 
 
 
 
 
 
 
 
Figure 6. BM histology in a patient with classical 5q- syndrome (H&E, 20x/40x objectives).  
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The 5q- phenotype is believed to be a manifestation of multiple allelic deletions 
located within a common deleted region (CDR). Initial work by Zhao et al. (1997) 
localized the CDR to a 1–1.5 Mb region on 5q31 in del(5q) patients with MDS and 
acute myeloid leukemia (AML) (174). Subsequent studies investigated the interstitial 
deletion on chromosome 5 in patients with the bona fide 5q- syndrome (175-177). The 
current accepted CDR was elucidated in a study involving sixteen 5q- syndrome 
patients with del(5q) as the sole karyotypic abnormality (178). Using FISH analysis, 
the CDR in the 5q- syndrome was delineated to a 1.5 Mb interval located on 5q32 
between the D5S413 marker and GLRA1 (178). This region included 44 genes such as 
phosphodiesterase 6A (PDE6A), CSF1R, CD74 molecule (CD74), Treacher Collins-
Franceschetti syndrome 1 (TCOF1), annexin A6 (ANXA6), SPARC and FAT tumor 
suppressor homolog 2 (FAT2) genes among others.  
Subsequent studies aimed at identifying and confirming the tumor suppressor gene 
associated with 5q- syndrome by global gene expression patterns. Using Affymetrix 
platform, Pellagatti et al (2006) identified unique gene expression signatures and 
down regulation of genes mapped to the CDR which separated patients with del(5q) 
from other MDS cases (148). Down-regulated genes encompassed the tumor suppressor 
gene SPARC. Interestingly, only SPARC was overexpressed in response to 
lenalidomide in a previous study from our group (179). However, the hematopoietic 
profile of 5q- syndrome patients is not reflected in SPARC null mice suggesting that 
it may not be the key gene responsible for the 5q- syndrome phenotype. An important 
study to further identify candidate genes in the “common deleted region” was 
undertaken by Boultwood et al (2007) who demonstrated that RBM22 and CSNK1A1 
were the two most significantly downregulated genes in the 5q- syndrome (180). 
Moreover, the ribosomal gene RPS14, mapping to this interval, showed 
haploinsufficiency in hematopoietic stem cells (HSC) from these patients.   
Ebert et al demonstrated that haploinsufficiency of RPS14 plays a critical role in the 
development of the anemia that characterizes the 5q- syndrome (181). Haploinsufficiency 
of RPS14 in normal HSC resulted in a block in erythroid differentiation and forced 
expression of an RPS14cDNA in BM cells from patients with 5q- syndrome “rescued” 
the phenotype, strongly suggesting that RPS14 is a “5q- syndrome” gene (181). Pellagatti 
et al found defects in several other genes involved in ribosomal biogenesis (182). The 
similarity of the genetic mechanism between the 5q- syndrome and other congenital 
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bone marrow disorders (Diamond-Blackfan anemia, Shwachman-Diamond syndrome) 
is remarkable and suggests a link between these two conditions. 
The recent  production of a knockout mouse model displaying a phenotype consistent 
with 5q- syndrome, in which the CDR was narrowed down to RPS14 and seven other 
genes, added to the evidence that RPS14  is a strong candidate for haploinsufficiency in 
human 5q- syndrome (183). However, this mouse model does not explain all 
characteristic features of the 5q- syndrome, as for example thrombocytosis, 
neutropenia and clonal dominance. Starczynowski et al. (2010) evaluated the 
expression of miRNAs located on chromosome 5q and found lower expression of 
miR-145 (5q33.1) and miR-146a (5q33.3) in individuals with del(5q) (184). 
Knockdown of miR-145 and miR-14a together recapitulated some features of the 5q- 
syndrome, such as increased platelet counts. From these two studies it may be 
speculated that del(5q) results in thrombocytosis and clonal dominance through 
reduction of miR-145 and miR-146a levels, whereas the haploinsufficiency of RPS14 
explains the macrocytic anemia. Since the RPS14 and miR-145 are closely related 
within the CDR, the combined loss may be sufficient to recapitulate the major 
features of the 5q- syndrome.    
 
2.6. Treatment and predictors of response 
The choice of treatment in MDS is based on clinical symptoms, risk groups and age. 
Whereas some patients may not require any treatment, others will need supportive care, 
chemotherapy or be eligible for allogenic stem cell transplantation. The Nordic MDS 
group has established guidelines for the treatment of MDS which are published at the 
website www.nmds.org. The different treatment options for MDS are as follows:  
 
2.6.1. Supportive care 
Supportive care includes red blood cell (RBC) transfusions for symptoms of anemia. 
The decision for transfusion should be made on an individual basis by the patient and 
the physician, taking into account co-morbidities and quality of life issues. No definite 
value for the requirement of RBC transfusions has been defined. Platelet transfusions 
are recommended in thrombocytopenic patients with moderate or severe bleeding.  
Protracted anemia requiring transfusion therapy can be expected in 40–80% of 
patients (185) with secondary iron overload and associated increased morbidity and 
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mortality (186). Retrospective studies have indicated survival benefit and decreased 
transfusion requirement in low-risk MDS patients who received adequate chelation 
therapy (187-189). Although the exact mechanism is not clear yet, improvement of 
hematopoiesis might be due to a reduction of oxidative stress in hematopoietic 
progenitors in general and erythropoietic progenitors in particular (190, 191).  A recent 
study demonstrated an iron overload dependent suppression of erythropoiesis in MDS 
patients and showed that the negative impact of toxic iron on the proliferation of 
erythroid progenitor cells may be in part reversible (191). There are no studies 
providing evidence of the effect of iron chelation on long-term outcome in MDS. 
Transfusion dependent patients with MDS should be treated according to 
international recommendations as established by a consensus working group on the 
basis of previous studies (192-194). 
Patients with MDS have an increased risk for infections due to neutropenia and this 
should be treated promptly and with follow-up of outcome. The routine use of 
prophylactic antibiotic treatment is not recommended as a rule but may be considered if 
infections start to occur. In addition, treatment with G-CSF can be considered as 
prophylaxis for severely neutropenic patients with recurring, serious infections or 
during infectious episodes.  
 
2.6.2. Erythropoietin 
Treatment with erythropoietin (Epo) may improve hemoglobin levels and alleviate 
transfusion need in MDS patient with anemia (195, 196). The effect of Epo may be 
enhanced by G-CSF (197-200). A large phase 3 prospective randomized trial with 
prolonged follow-up evaluated the efficacy and long-term safety of erythropoietin 
(EPO) with or without granulocyte colony-stimulating factor plus supportive care 
(SC) versus SC alone for the treatment of anemic patients with lower-risk 
myelodysplastic syndromes (201). The response rates in the EPO versus SC alone arms 
were 36% versus 9.6%, respectively. No differences were found in OS or in the 
incidence of transformation to acute myeloid leukemia (201). 
Taken together, there is no doubt that a major portion of patients with MDS and 
symptomatic anemia may have substantial clinical benefit from treatment with hema-
topoietic cytokines without evidence of enhanced adverse consequences. Patients 
should be evaluated according to a predictive model including S-erythropoietin and 
level of transfusion need before a final decision about treatment is made (202, 203). 
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2.6.3. Immunosuppressive therapy 
The current data on immune suppressive therapy (IST) indicate that these drugs, as a 
class, are effective in a specific subgroup of MDS; younger low-risk MDS with 
normal karyotype and no ring sideroblasts. In this rare subgroup, 30-50% of patients 
respond to this treatment  (139, 142, 143, 204-210). IST is most effective in the early phase of 
lower-risk MDS, and HLA-DR 15 positivity, young age and short duration of RBC 
transfusion dependence seem to predict for treatment response, although this is based 
on limited material (211) (145, 212, 213). The administration of IST in MDS does not appear 
to increase the risk of disease progression (145). 
 
2.6.4. Azacytidine  
Treatment with demethylating agents (e.g., azacytidine and decitabine) is today first-
line treatment in most patients with higher-risk MDS and results in better response rates 
as compared to supportive care (129, 214, 215). In a recent randomized study that compared 
Azacytidine treatment with conventional care in patients with high-risk disease, the 
median survival was 24 months in the Aza-treated patients as compared to 15 months 
in the conventional-care group and leukemic transformation was delayed (214).  Other 
studies found that the combination of azacitidine and lenalidomide was highly effective 
and well-tolerated in patients with higher-risk MDS (216, 217). The rationale for this 
therapy is suggested to rest on the complementary action of these two compounds. 
Lenalidomide works through inhibition of phosphatase activity in the CDR of 
chromosome 5 leading to a stabilization of Mdm2 and p53 degradation (218, 219), via 
the upregulation of mir145 (220), direct cytotoxic mechanisms and through effects on 
the BM microenvironment, whereas AZA inhibits methyltransferase activity and acts 
via direct cytotoxicity.  
 
2.6.5. Induction chemotherapy 
There is no evidence that AML-like chemotherapy alters the natural history of MDS, 
i.e. long-term survival is not affected by the treatment. In addition, there are no data to 
support that high dose chemotherapy with autologous stem cell transplantation is 
superior to AML-like chemotherapy. AML like chemotherapy may be considered in 
younger patients with high-risk MDS (IPSS INT-2 or HR) and MDS-AML, prior to 
allogeneic SCT, and in selected patients not eligible for allogeneic SCT. In elderly 
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patients with high-risk MDS (IPSS INT-2 or HR) and MDS-AML (<30% blasts), 
azacytidine is recommended as first choice.  
 
2.6.6. Allogeneic stem cell transplantation 
The only curative therapy for MDS is allogeneic stem cell transplantation (SCT) (221) 
(222-225) which is first-line therapy for patients with INT-2 and high-risk MDS with an 
available donor, if age and co-morbidities allow for the risk of the procedure. Since the 
intensity of transplant conditioning contributes to non-relapse mortality, the 
development of reduced-intensity conditioning (RIC) regimens and the use of 
alternative donor sources have allowed for SCT also in older patients. Nevertheless, 
cumulative mortality rates after SCT are still considerable (226), predominantly due to 
graft-versus-host disease (GVHD) and relapse. Available data suggest that only one 
third of older patients experience long-term disease-free survival (227, 228). Therefore, 
allogeneic HCT in its current form needs to be further developed and improved. With 
the help of novel molecular markers and improved prognostic scores, patients may be 
better stratified according to the disease risk and potential benefits of allogeneic HCT. 
 
2.6.7. Lenalidomide in del(5q) MDS 
Lenalidomide (len) represents the first targeted therapy for MDS and is approved by the 
Food and Drug Administration (FDA) for red blood cell (RBC) transfusion dependent 
patients with lower risk MDS and an interstitial deletion of a segment of the long arm 
of chromosome 5 (del(5q)). The specific activity in del(5q) MDS was first observed in 
the MDS-001 study (229) in which 12 of 43 low-risk patients had del(5q) and 83% of 
these responded. The unique activity in lower-risk del(5q) MDS was confirmed in a 
subsequent MDS-003 study (230) which led to the FDA approval. By contrast, EMA did 
not approve the drug as they could not exclude an association between treatment and 
leukemic transformation. The randomized double-blind phase III MDS-004 trial aimed 
to validate the finding from MDS-001 and MDS-003 studies (231); 205 patients were 
randomized to either 10 mg lenalidomide days 1-21 every 28 days, 5 mg daily, or 
placebo. The RBC-transfusion independence rate (≥26 weeks) was 56%, 42% and 6% 
for lenalidomide 10 mg, 5 mg and placebo, respectively, with corresponding 
cytogenetic response rates of 29%, 15% and 0%. Median duration of transfusion 
independency in the 004 study was approximately two years, and the three year overall 
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survival and AML risk were 56% and 25%, respectively in the lenalidomide cohorts 
combined.  
Patients with del(5q) MDS and an increase of medullary blasts up to 10% were eligible, 
as long as they fulfilled the criteria of intermediate-1 risk disease. It was shown that 
patients with an increased blast count had similar response rates to patients with <5% 
blasts and consequently, additional attempts to treat patients with del(5q) MDS and 
≥5% BM blasts were carried out (232). The first study using the same doses as for lower-
risk del(5q) confirmed efficacy also in this population with similar cytogenetic 
response rate of 67% as for low- and INT-1 risk del(5q) patients, but only in patients 
with isolated del(5q), while patients with del(5q) + 1 additional abnormality had a 
response rate of 9% and patients with complex karyotype did not respond at all (232).  
The use of lenalidomide in non-del(5q) lower-risk, transfusion dependent MDS was 
examined in the MDS-002 clinical trial (233). This study had similar inclusion criteria 
and treatment schedule as the MDS-003 trial apart from the exclusion of patients with a 
del(5q) cytogenetic abnormality. The study enrolled 214 patients; 40% had RARS, and 
the majority of patients were low or INT-1 IPSS risk. The overall response rate was 
43%, 26% of patients became transfusion-independent and 17% had a ≥50% reduction 
in transfusion requirements with a median response duration of 41 weeks.  
The observed difference in clinical responses between patients with del(5q) and non-
del(5q) MDS led to the understanding of a karyotype-specific mechanism of action. In 
del(5q) MDS, lenalidomide exhibits actions on both the benign and the malignant 
progenitor population. The ability to induce apoptosis of progenitors harboring the 
del(5q) abnormality is thought to be linked to the haploinsufficiency of one or several 
genes on the long arm of chromosome 5. The fact that patients usually achieve TI 
within 4-5 weeks, before achieving cytogenetic remission, supports the concept of 
activation of residual normal erythropoiesis. Lenalidomide has also anti-angiogenic and 
anti-inflammatory properties (234, 235). In non-del(5q) disease, lenalidomide seems to 
enhance response of erythroid precursors to different stimuli, including erythropoietin. 
This is supported by the fact that lenalidomide promotes erythroid progenitor formation 
and expansion in CD34+ cells from healthy donors in vitro (236). 
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Figure 7. Suggested mechanism of action of lenalidomide in del(5q) MDS. Nuclear 
liberation of free ribosomal proteins as a result of impaired ribosomal biogenesis leads to  
degradation of the MDM2 gene protein, stabilization of p53, and increased apoptosis in 
del(5q) MDS. In addition, len inhibits the haplodeficient PP2A phosphatase and Cdc25c and 
phosphorylates MDM2 leading to protein stabilization, and p53 degradation (adapted from R. 
S. Komrokji and Alan F. List, Semin Oncol 38:648-657, 2011). 
 
The role of lenalidomide in the treatment of del(5q) MDS has been reviewed in a 
number of recent papers which also addressed the question whether treatment with len 
increases risk of AML transformation in certain patients (237-239). Most data suggest that 
the risk of AML progression of del(5q) patients is dependent on individual risk factors 
before treatment initiation indicating that lenalidomide per se is not leukemogenic. 
However, a prospective randomized study with this question as endpoint has not been 
performed. 
 
2.6.8. Predictors of response 
To date, there are no widely used biomarkers for therapeutic decision-making in MDS 
other than del(5q) for lenalidomide according to the US label, and S-EPO levels plus 
degree of transfusion need for predicting response to erythropoiesis-stimulating agents. 
A recent study demonstrated that FCM may add to known predictive parameters in 
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selecting MDS patients eligible for EPO/G-CSF treatment (240). In addition, somatic 
mutations may serve as such biomarkers if they can be shown to consistently predict 
response to treatment. For example, in a recent phase II study of Len and Aza 
combination in patients with higher-risk MDS, the presence of TET2, DNMT3A, IDH1 
or IDH2 mutations was predictive of complete response, even in the presence of other 
somatic mutations that ordinarily carry a bad prognosis in MDS (217). In another 
retrospective study of 86 patients with MDS treated with Aza, the presence of a TET2 
mutation was associated with an 82% response rate, compared to a 45% response rate 
in TET2 wild-type patients (241). Additional studies designed to identify genetic 
predictors of response to different treatment modalities in both low- and high-risk MDS 
will be critical for tailoring appropriate therapy to each patient.  
 
 
3. THE TP53 GENE 
3.1. A brief history 
In 1979 several groups reported on a protein (p53) that formed a complex with the 
SV40 tumor-virus oncoprotein, the large T-antigen (242, 243). The p53 protein was 
initially considered as tumor antigen, eliciting an antibody response, when transformed 
mouse cells produced tumors in mice (244). It was postulated that p53 might be a cellular 
oncogene product linked to the viral transformation process (243). Further studies 
revealed the p53 protein was involved in viral replication and tumorigenesis by small 
DNA tumor viruses (245-247).  Isolation of p53 DNA clones and the demonstration that 
many of these cDNAs could transform cells in combination with the Ras oncogene (248-
250) established p53 as an “oncogene”. Later, it became clear that these transforming 
DNA clones contained a mutation and that the wild-type DNA in fact was capable of 
suppressing tumor growth in vivo.  Indeed, mutations in both p53 alleles were found in 
mouse tumors (251), human cell lines (252) and in the DNA from human colon cancers 
(253). In 1990 alterations of p53 were detected in Li-Fraumeni syndrome, a disease 
characterized by the early onset of cancers (254). Researchers also found that p53 
knockout mice were prone to cancer (255, 256). Together, these findings led to the 
assumption that p53 was the ultimate tumor suppressor gene (257). P53 is now 
recognized as a pivotal regulatory protein that reacts to a variety of signals and recruits 
an array of biochemical activities to trigger diverse biological responses, most notably 
cell-cycle arrest and apoptosis. P53 is also known to be involved in differentiation and 
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development, DNA repair, DNA replication and transcription, senescence and cell-
cycle checkpoints (258). 
 
3.2. Structure and Function of p53 
The TP53 gene is located on the short arm of chromosome 17 (17p13), and spans 20 
kbases with 11 exons. Its protein is organized into five domains (Figure 8), each 
corresponding to specific functions: the amino-terminus contains the acidic 
transactivation domain, the mdm2 protein binding site, and the Highly Conserved 
Domain I (HCD I); region 40-92 contains repeated proline residues and a second 
transactivation domain; the central region (101-306) contains the DNA binding 
domain and is target of 90% of TP53 mutations found in human cancers; the 
oligomerization domain (307-355, 4D), the carboxy-terminus of p53 (356-393) and a 
non-specific DNA binding domain that binds to damaged DNA.  
 
Figure 8. Structural organization of the TP53 gene and protein (http://p53.free.fr). 
 
The p53 pathway (reviewed in (259)) may be divided into five parts: the stress signals 
that activate the pathway, upstream mediators that detect and interpret those signals,  
the core regulation of p53 through its interaction with several proteins, downstream 
events composed of a set of genes and their proteins that are regulated by p53, and 
final outcome including cell cycle arrest, cellular senescence, apoptosis or DNA 
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repair. Briefly, under normal cellular conditions p53 is held in an inactive state and 
maintained at a low level by rapid degradation (260). In response to a range of cellular 
stresses, including DNA damage, p53 expression is upregulated and acts as a 
transcription factor for a number of genes that induce cell cycle arrest, apoptosis, 
senescence or DNA repair (261-266) . The discovery of the MDM-2 oncogene, a p53 
binding protein and major negative regulator of p53 levels, provided insights in how 
p53 was regulated by these diverse stress signals (267-270). For instance, p53 may be 
activated by various perturbations of ribosomal biogenesis including reduced levels of 
ribosomal proteins (271) or by the release of ribosomal proteins from the nucleolus, most 
notable RPL11, during ribosomal stress (272). The ribosomal proteins then bind MDM2 
which leads to the accumulation of p53 protein via inhibition of MDM2 (273, 274). 
Activated p53 then promotes the transcription of its target genes resulting in p53-
dependent cell cycle arrest, senescence, or apoptosis (275). Thus, p53 and MDM2 are 
linked in an autoregulatory feedback loop in which p53 induces the transcription of 
MDM2 while MDM2 promotes p53 degradation (276). More recently, p53 was found to 
counteract the rate of and the efficiency of reprogramming differentiated cells by 
adding transcription factors into more pluripotent stem cells (277), indicating the 
influence of the p53 protein on developmental decisions.  
The functions of the p53-response genes fall into several categories, including genes 
involved in cell cycle arrest (p21, 14-3-3 sigma, GADD-45) and intrinsic (bas, noxa, 
puma) and extrinsic (Fas, DR5) apoptotic pathways. 
 
Figure 9. The p53 pathway with its core regulation through interaction with proteins that 
modulate its stability, downstream events and final outcome. (http://p53.free.fr) 
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Several other p53-regulated genes have been implicated in the enhancement of 
apoptosis, but their mechanisms of action remain to be elucidated. One of the main 
unanswered questions is how p53 “decides” to trigger the pro-survival or cell death 
responses. It has been documented that depending on the tissue and cell type, the nature 
and intensity of the stress signal, and the extent of cellular damage, p53 would favor 
one response to another (278-280). 
 
3.3. TP53 mutations in cancer 
Mutations of the TP53 gene are the most common and most frequently studied 
molecular alterations in human cancer (281, 282). In hematological malignancies, TP53 
mutations have been reported to occur at frequencies ranging from 5% to 50% (283, 
284). Data on mutation prevalence including TP53 gene variations found in human 
cancers are compiled in the IARC TP53 database (http://www-p53.iarc.fr/).  
Mutations in the TP53 gene or inactivations of its signaling pathway result in altered 
and stable p53 proteins that function as dominant negative with “gain-of-function” 
properties, including drug resistance, and contribution to malignant progression (256, 
285, 286). Most mutations occur within the central DNA binding domain (exon 5-8) and, 
in particular, at specific amino acids required for DNA binding. Inactivation of the 
p53 gene is essentially due to small mutations (missense and nonsense mutations or 
insertions/ deletions of several nucleotides), which lead to either expression of a 
mutant protein (90%) or absence of protein (10%). Thus, TP53 mutations may confer 
loss of function whereas others have a dominant negative effect, and still others are 
classified as wild-type like protein and represent mutant forms with a limited biological 
effect (287, 288). In addition, various proteins acting upstream of or downstream from 
p53 in its signaling networks are frequently mutated in human cancers. Indeed, 
mutational disruption of the p53 network may occur in most aggressive endstage 
cancers (289). 
Inactivation of p53 gene expression by hypermethylation of transcription promotors 
has not been demonstrated, which supports the hypothesis of a function for p53 
mutants. Mutations in the p53 pathway, inherited single-nucleotide polymorphism 
(SNP) and copy-number variations are continuously uncovered and may add useful 
clinical information.  
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3.4. Immunohistochemistry 
Detection of TP53 mutation is a complex, relatively expensive method, which currently 
is difficult to integrate into daily routine practice. In comparison, p53 IHC is a ready 
available, inexpensive and easy technique used in many pathology laboratories.  
Monoclonal antibodies (mAbs) directed against the p53 protein have been invaluable 
tools for both clinical and basic research. In the area of basic research, these mAbs 
have permitted detailed studies of the various conformations of the p53 protein. More 
than 95% of the various mAbs recognize epitopes which are localized in the amino, 
or (to a lesser extent) in the carboxy terminus of the protein. Table 5 lists 
commercially available human p53 mAbs out of over 100 anti-p53 mAbs described in 
the literature (290-297). 
 
Table 5.  Human p53 Monoclonal antibodies 
Name Epitope  Localization Antigen used for immunization Reference 
DO2 10-16 Amino-terminus human p53 296, 297 
DO7 21-25 Amino-terminus human p53 
DO1 21-25 Amino-terminus human p53 
BP53-12 20-25 Amino-terminus human p53 295, 297 
PAb1801 6-55 Amino-terminus human p53 298, 294 
Pab240 213-217 Central region murine p53 299, 297 
HO8.1 306-361 Carboxyterminus human p53 301 
Pab122 371-380 Carboxy-terminus mouse p53 300 
Pab421 371-380 Carboxy-terminus mouse p53 300, 297 
 
Scoring of p53 and Reproducibility 
The vast majority of p53 immunohistochemical studies have been performed on 
epithelial cancers. Immunohistochemical staining for protein expression analysis in 
formalin-fixed tissue is usually scored manually and semi-quantitatively. However, the 
lack of uniform scoring systems, failure to use a consistent definition of what 
constitutes p53 “overexpression” and the use of different protocols for IHC make data 
from these studies difficult to compare and interpret. In addition, the readout may be 
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influenced by the type and length of tissue fixation, the age of the fixed tissues and 
slides before staining, the method of antigen retrieval, and the type of antibody used. 
Whereas some studies simply used a cut-off of 10% or more for defining p53 positivity, 
others employed complicated scoring systems, which take into account both the 
quantity of positive cells, as well as the staining intensity (298-304). One study assessed 
the interobserver reproducibility by using the 0% cutoff (0% staining vs. any staining), 
the 10% cut-off (≤10% nuclear staining vs. >10% staining) and a three-category scoring 
system consisting of 0%, 1-50% and >50% staining (305). Excellent agreement was 
achieved when no positivity (0%) vs any positivity was calculated (light’s kappa 
coefficient k=0.831), whereas the three-category scoring system produced the lowest 
amount of agreement between observers. In another study, p53 expression was simply 
measured as the percentage of tumor cells with any positive nuclear staining since 
moderate-to strong staining intensity was observed in a very large fraction of tumor 
cells, and the inclusion of staining intensity would not have improved performance of 
the test at the chosen cut-off level (306). The assessment of staining intensity can be 
problematic as it may be difficult to reproduce and it can vary with different 
protocols. However, the presence of strong nuclear staining has in several studies been 
associated with higher tumor grade and aggressiveness (304, 307, 308). By contrast, the 
presence of weakly positive nuclei (a pattern commonly associated with wild type 
TP53) can serve as internal positive control.  
Known TP53 polymorphisms do not represent gene mutation and most of them are 
expected to be phenotypically silent (302, 309) However, it is not entirely clear whether 
TP53 polymorphisms may or may not result in conformational changes leading to 
altered immunoreactivity of p53 (310). 
 
Computer-assisted immunohistochemical scoring  
The introduction of the high-throughput method of tissue microarrays (311) has spurred 
the need for automated image analysis and quantification methods for scoring of stains. 
(312-314) Computer-assisted immunohistochemical scoring could be used as alternative to 
manual scoring with possible benefits including reproducibility, reliability and time-
effectiveness, but are still relatively uncommon in routine laboratory practice (315, 316). 
A number of studies have compared manual and computer assisted scoring and found 
good levels of agreement between both techniques, however, automated image analysis 
showed higher sensitivity in some studies (317, 318). 
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P53 protein expression as a prognostic marker 
A large number of studies have found p53 overexpression to be a strong prognostic 
marker in human cancer (303, 304, 319-329), although this result has not been obtained 
uniformly (330-333). There are a number of possible explanations for these 
inconsistencies, including small numbers of patients drawn from patient populations 
with varying treatments and clinical characteristics, the use of different IHC protocols 
and p53 antibodies, and different scoring criteria.  
 
P53 protein expression and TP53 mutation  
Unlike wild-type p53, mutated p53 has a prolonged intracellular half-life and therefore 
becomes detectable by IHC (334-336). Thus, IHC detection of p53 has been considered a 
surrogate marker of p53 gene mutation (335, 337). A number of studies have shown a 
strong correlation between p53 protein expression by IHC and mutation by DNA 
sequencing (338-342). However, identification of p53 nuclear accumulation in tumor cells 
in the absence of gene mutation has been noted, indicating alternative mechanisms of 
acquiring a p53 positive phenotype (343-345). One of the major factors contributing to 
p53 stabilization is via expression of p14ARF (346-348). Alternatively, inhibition of 
MDM2-mediated degradation of p53 could block the degradation of p53 protein (349-
351). Other possible explanations could be that mutational analysis often evaluates 
codons 4 through 9, which would identify most, but not all possible mutated loci. In 
addition, the sample on which mutational analysis is carried out may not be the same 
used for IHC, and it is conceivable that tumor heterogeneity or the heterogeneity of 
the population itself could account for discordant findings. The lack of 
immunohistochemical expression may result from a nonsense mutation leading to 
formation of a truncated, non-immunoreactive protein.  Indeed, tumors with no p53 
expression have been shown to have a higher frequency of protein-truncating TP53 
mutations compared with p53-positive tumors (352, 353). This is important to recognize 
because some studies demonstrated worse prognosis for patients with this finding 
compared to patients with missense mutations (354) (355).Consequently, p53 IHC detects 
a large fraction of TP53 mutations, but not all (356-358). It is therefore not surprising 
that studies in various human cancers correlating TP53 gene status and/or p53 
overexpression with clinical outcome and response to chemotherapy have reported 
conflicting results (300, 326, 357, 359-362). 
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In summary, the use of p53 in clinical practice, as a marker for cancer progression and 
therapeutic target, calls for a need for validation of IHC (363, 364). In addition, 
immunohistochemical staining patterns of p53 expression should be correlated with 
mutational analysis in order to establish practical cut-offs for different tumor types 
and tissues which can be used to infer the presence of a TP53 mutation. 
 
3.5. Targeting p53 in the clinic 
The high frequency of TP53 mutations in human tumors and the often observed 
increased resistance of mutant p53-expressing tumors to conventional chemotherapy 
makes mutant p53 an attractive target for novel cancer therapy (365). In addition, there 
are a number of studies demonstrating that the type and position of a p53 mutation in 
the DNA binding domains of the p53 gene in cancers has prognostic value (286). Drugs 
that act preferentially on cells with certain TP53 missense mutations have been 
identified and represent a new approach for treatment. An animal model showed the 
reactivation of wild-type p53 to result in efficient tumor regression, including 
regression of lymphoma (366, 367) and liver carcinoma (368). There is a class of small 
molecules that reactivate the wild-type functions of mutant p53 (369). Bykov et al. 
identified PRIMA-1 and the structural analog PRIMA-1Met, also named APR-246 
(370, 371). These compounds restore wild type conformation to mutant p53 and have 
shown to inhibit tumor growth in a mutant p53-dependent manner (372). 
PRIMA-1 and PRIMA-1Met/APR-246 induce p53 targets such as p21, MDM2, Bax, 
Noxa, Puma, 14-3-3, GADD45, and PIDD according to several studies (373-375), and 
have been tested in primary leukemic cells from AML and CLL patients (376, 377), and 
in a recent phase I clinical trial in patients with hematological malignancies and 
prostate cancer (378). 
Many tumors, even those without TP53 mutations, overexpress MDM2, making 
targeting of MDM2 for p53 stabilization another promising approach for cancer 
therapy. For example, the nutlins are compounds that act as antagonists of the 
MDM2-p53 interaction. Analysis of the crystal structure showed that nutlin binds in 
the pocket of MDM2 to prevent the p53-MDM2 interaction. Nutlin can activate the 
p53 pathway, thereby inducing cancer cells and xenograft tumors in mice to undergo 
cell cycle arrest, apoptosis, and growth inhibition (379, 380). Issaeva et al. screened a 
chemical library and found the small molecule RITA (reactivation of p53 and 
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induction of tumor cell apoptosis), which binds to p53 and inhibits the p53-MDM2 
interaction both in vitro and in vivo (381). RITA induced apoptosis in various cancer 
cells that retained wild type p53. It was also found that p53 released from MDM2 by 
RITA promotes p21 and hnRNP K (a p53 cofactor), implying that p21 plays a major 
role in regulating the cancer cell fate after p53 reactivation (382). Recent reports have 
shown that p53 regulates the process of self-renewal of neural stem cells (383) and 
hematopoietic stem cells (80). 
In view of the cancer stem model, proposing that tumors are maintained by a small 
population of cancer stem cells that can divide both symmetrically and 
asymmetrically, further investigation of the link between the p53 function and cancer 
stem cells may therefore be one of the most important research fields for new 
paradigms in cancer therapy. 
 
 
4. THE TP53 PATHWAY IN DEL(5Q) MDS  
 
4. 1. Activation of the TP53 pathway 
Several studies have demonstrated an important pathophysiologic role for p53 in the 
5q- syndrome where haploinsufficiency of the RPS14 ribosomal protein appears to 
drive the anemia of this disease (181, 183, 384). It was shown by several groups that BM 
progenitor cells in 5q- patients show an accumulation of p53 protein reflecting 
increased apoptosis (92, 183, 218). Using mouse models, it was demonstrated that the 
progenitor cell defect in “5q- mouse” was rescued by crossing them with p53 deficient 
mice (183). This important finding was supported also by studies in human 5q- syndrome 
(92), and suggested that a p53 dependent mechanism underlies the pathophysiology of 
the 5q- syndrome. By using gene expression profiling, it was shown that ten genes in 
the p53 pathway (FAS, CD82, WIG1, CASP3, SESN3,TNFRSF10B, MDM4, BAX, DDB2 
and BID) were significantly deregulated (92). All these genes (with the exception of 
MDM4, a negative regulator of p53) were expressed at higher levels in the 5q- 
syndrome compared to healthy controls. Moreover, 5 of the 8 most significantly up-
regulated known genes in 5q syndrome are p53 targets, including WIG1 and BAX 8. 
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Figure 10. Activation of the TP53 pathway by haploinsufficiency of the RPS14 ribosomal 
protein or TP53 mutation in del(5q) MDS – both resulting in p53 protein accumulation. 
 
In another recent study, it was shown that p53 activation occurred selectively in 
erythroid progenitor cells resulting in the accumulation of p53 protein in erythroid 
precursors, cell cycle arrest and apoptosis (384). Moreover, pharmocologic inhibition of 
p53 by the p53 inhibitor PFT-alpha rescued the erythroid defect. In comparison, Xu et 
al found that by treating NHD13(+) Tg MDS mice with the p53 inhibitor Pifithrin-
alpha (PFT), the myeloid and lymphoid lineage differentiation defects were partially 
rescued, however with only temporarily improvement of hematopoiesis (385). Instead, 
chronic deficiency in p53 function accelerated ineffective hematopoiesis and 
progression to AML indicating that rather than blocking p53 function, promoting its 
function, or triggering its downstream effects, may help eliminate MDS clones. The 
findings are significant since they indicate that patients may benefit from 
pharmacological manipulation of the p53 pathway - in one way or the other.  
A recent study by Zhao et al (2010) showed that loss of p53 in myeloid progenitor 
cells established aberrant self-renewal, paving the way for AML development (386). 
Although it could not be ruled out that additional functions of p53 contributed to 
tumor suppression in this context, the de novo acquisition of self-renewal in cells that 
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normally lack this capability could be a key function of p53 mutations in MDS and 
AML. Accordingly, loss of p53 might contribute to the formation of leukemia-
initiating cells, which by definition have maintained or reacquired the capacity for 
indefinite self-renewal through accumulated mutations and/or epigenetic changes (387). 
These cells have properties reminiscent of cancer stem cells, which are considered to 
be inherently more aggressive and refractory to chemotherapy (388, 389). 
Thus, p53 plays a pivotal role in the development and progression of del(5q) MDS 
including both p53 wild type activation - leading to increased apoptosis and defective 
erythropoiesis – and TP53 mutation. 
 
4.2. TP53 mutations  
TP53 mutations occur primarily in high-risk/therapy related MDS, MDS-derived 
leukemia and in context of complex chromosomal abnormalities including del(17p) (390-
403). These studies reported also on the poor prognostic impact of TP53 mutations and 
the association with poor therapy response. The Appendix (11.) lists references from a 
literature review. TP53 mutations in lower-risk MDS are only rarely reported in these 
previous studies (400, 404), which may be explained by the use of conventional 
sequencing techniques with a lower sensitivity level but also that fewer studies 
investigated TP53 mutations in this subgroup of MDS patients. The development of 
deep-sequencing has made it possible to screen for mutations at greater depth. 
Interestingly, a high frequency of chromosome 5 and 7 abnormalities was found in 
patients with TP53 mutations (395, 399, 403, 405, 406). Some studies assessed both TP53 
mutation status and p53 by IHC (335, 404, 407) with generally good concordance between 
the two methods. Lepelley et al compared the value of immunocytochemistry on blood 
and BM slides with Sanger mutation analysis and found that immunocytochemistry 
allowed detection of mutation in a smaller percentage of cells (335). 
Recently, Machado-Neto et al investigated the frequency of MDM2 SNP309 and TP53 
Arg72Pro polymorphisms in de novo MDS and the association of these polymorphisms 
with clinical characteristics. It was shown that the frequencies of genotypes for MDM2 
SNP309 and TP53 Arg72Pro did not differ between MDS and healthy controls, and 
were not associated with clinical and laboratory parameters, disease progression and 
overall survival. This suggests that MDM2 and TP53 polymorphisms are not involved 
in the pathogenesis or in the clinical and laboratory characteristics of MDS (408). 
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5.  AIMS OF THE THESIS 
 
The purpose of this thesis was to study the role of TP53 mutations in myelodysplastic 
syndromes with a deletion of chromosome arm 5q.  
 
Specific aims were:  
 
I. To assess p53 protein expression as a marker for outcome in lower-risk 
del(5q) MDS 
II. To investigate the correlation between p53 expression measured by 
immunohistochemistry and TP53 mutation  
III. To assess the impact of p53 protein expression in bone marrow cells on 
treatment response to lenalidomide 
IV. To determine the effect of lenalidomide monotherapy in higher-risk MDS and 
AML with del(5q) abnormality in relation to molecular markers 
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6.  MATERIALS AND METHODS 
 
Paper I was a hypothesis-generating case observation, which was followed by two 
subsequent studies including 55 and 85 low-/INT-1 risk del(5q) MDS patients, 
respectively. Paper III was a prospective phase II multicenter trial which enrolled 28 
patients with high-risk MDS and AML from three participating countries within the 
Nordic MDS group. 
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6.1. Paper I, II and IV 
Paper I describes the clinical course of a patient with classical 5q- syndrome who, after 
complete erythroid and partial CyR to lenalidomide, evolved to high-risk MDS with 
complex karyotype after 22 months from start of treatment. The clinical course of this 
patient was unexpected, however cases with similar features have been observed by us 
and others (personal communication and ref. (409)) which raised the question whether 
“good-risk” del(5q) MDS really represented a uniform subgroup as proposed by the 
WHO classification. We therefore aimed to identify additional markers beyond 
established risk score parameters, which may have contributed to disease progression in 
this patient. We reviewed BM and PB samples from the entire clinical course and 
performed IHC. Cytogenetic and molecular studies included chromosome banding 
analysis and FISH using probes for the locus 5q31, the MLL-locus (11q23), RB1-locus 
(13q14), TP53-locus (17p13), bcl2-locus (18q21), and AML1-locus (21q22). CD34+ 
progenitors were selected from BM mononuclear cells and gene expression profiling 
analysis was performed as previously described (148, 179). TP53 mutation analysis was 
performed by polymerase chain reaction (PCR) using published primer sequences.  
In a subsequent study (Paper II), we investigated the frequency of TP53 mutations in a 
cohort of 55 patients with low-/INT-1 risk del(5q) MDS (Manuscript p. 1974, Table 
1). All patients were risk-classified (IPSS/WPSS) and followed until February 2010 
for survival, disease progression, and treatment. BM samples (n=148) were reviewed 
and stained for p53. TP53 mutations were analyzed from DNA isolated from archived 
BM smears (n=89) or BM Ficoll-separated mononuclear cells (n=16) using the Roche 
GS FLX sequencing platform (Roche, Indianapolis, IN). 
The primary objective in paper IV was to validate p53 IHC as an independent 
prognostic marker for outcome in MDS as indicated by previous findings (Paper I and 
II). This was a retrospective correlative study for which 131 FFPE BM trephines were 
retrieved from 85 of the 205 patients (IHC cohort), who had been enrolled in the 
recently published, phase III randomized, double-blind MDS004 clinical trial (231).  
The BM biopsies were assessed in a blinded fashion for the percentage of p53 staining 
cells, and the intensity of p53 nuclear staining was graded as 0 (negative), 1+ (weakly 
positive), 2+ (moderately positive) and 3+ (strongly positive). A computerized 
automated imaging system was used to measure p53 positive stained nuclei/total 
scanner cell count for comparison with manual counts.  
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Figure 11.  p53 score by automated image analysis; strong (red circle, 3+), moderate (orange 
circle, 2+), weak (yellow circle, 1+), negative nuclear staining (blue circle, 0) 
 
TP53 deep-sequencing mutation analysis was possible only in a subset of nine (11%) 
consenting patients using DNA from FFPE BM tissue. Laser-assisted microdissection 
of p53 immunolabeled cells was performed to study the relation between protein 
expression and TP53 mutation by pyrosequencing analysis.  
 
6.2. Paper III 
This prospective phase II multicenter trial enrolled 28 patients with high-risk MDS 
and AML with chromosome 5 abnormalities who were not eligible for standard 
therapy (Manuscript p. 966, Table 1). The majority of patients had failed 1 or 2 
previous lines of therapy. The patients were treated with increasing doses lenalido-
mide to a maximum dose of 30 mg daily. The total study period was 16 weeks. Three 
patients had isolated del(5q), six had del(5q) plus one additional aberration, 14 had 
del(5q) as part of a complex karyotype, four had monosomy 5, and one had del(5q) 
identified by FISH only. The main objective of the trial was to study the efficacy of 
len to inhibit the tumor clone containing del(5q) or monosomy 5. Primary endpoint 
was major CyR (assessed by FISH) after 16 weeks treatment. Secondary objectives 
were safety of increasing doses of len, other hematologic responses and the predictive 
value of a series of biomarkers for response to treatment. BM histology and cytology-
cal preparations from BM and PB were centrally reviewed at inclusion and week 16; 
IHC was performed on all samples. Genetic markers were assessed including the 
WT1 transcript and P21 expression in relation to P53 mutational status (exons 5-9). 
FISH analysis was used to establish the baseline percentage of del(5q) cells.  
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7.  RESULTS AND DISCUSSION 
7.1. Paper I, II and IV 
The clinical course with results from serial BM assessment and TP53 mutation analysis 
of the patient described in Paper I is shown in Figure 12A. In the same manner, we 
assessed the association between p53 IHC, TP53 mutation and outcome in three other 
patients who were enrolled in the MDS004 clinical trial (Figures 12 B-D). Briefly, 
two patients (A and B) had small TP53 mutated subclones already at initial diagnosis 
which remained initially stable but increased as the patients progressed to high-risk 
MDS. The TP53 mutation was reflected by the presence of BM progenitors with 
strong p53 staining at the corresponding time points. The other two patients (C and 
D) acquired TP53 mutations at 52 and 75 months, respectively, associated with an 
increase in p53 by IHC. The acquisition of TP53 mutations was associated with rapid 
disease progression. 
 
 
 Figure 12. Clinical course of four patients with classical 5q- syndrome and TP53 mutations 
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Serial BM samples were then assessed in a subset of 21 patients (25%) from the IHC 
cohort (Paper IV). At the scheduled 12 week’s assessment, an increase in p53 
expression was seen in eight patients which was associated with cytogenetic evolution, 
increased AML risk (p <0.01) and shorter OS (p=0.0005) compared to patients who 
remained negative for p53. 
 
 
Figure 13. p53 stain at diagnosis (upper left) and follow-up (upper right) in a patient with 
cytogenetic evolution after 12 months from randomization date (20x objective). Cells with 
strong nuclear p53 expression are positive for Hemoglobin (lower left) and mostly negative for 
CD34; aberrant CD34 expression in megakaryocytes (lower right).  
 
Single cell laser-microdissection of p53-immunolabeled cells was performed to study 
the relation between strong p53 protein expression and mutation. Indeed, the mutant 
allelic burden in micro-dissected cells with strong p53 staining was around 45% 
indicating that 90% of the cells carried the mutation (Manuscript, Figure 1).  By 
contrast, cells from the same sample with moderate (2+) p53 staining were 
predominantly wild-type TP53 (allelic burden around 16%). 
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TP53 deep sequencing analysis detected mutations in 10 of 55 (18%) (Paper II) and in 
3 of 9 evaluable patients (Paper IV). Nine of 10 patients with TP53 mutation had ≥2% 
of p53 strong cells, and all four patients with ≥5% p53 were mutated. By comparison, 
2 of 3 patients with TP53 mutation had strong p53 expression (<2%) while the other 
patient carried a K291 nonsense mutation and was negative by IHC, as expected.  
The presence of a TP53 mutation was significantly associated with outcome (Paper II, 
p.1977, Figure 2). In addition, we found a strong correlation between p53 protein 
expression by IHC and outcome using both ≥1% and ≥2% cut-off levels (Manuscript, 
Paper IV).  
In summary, we were first to show that TP53 mutated subclones occur in a subset of 
lower-risk MDS with isolated del(5q), and that these may be an important driver of 
leukemic transformation. A recent study described TP53 mutation at a similar 
frequency in this subgroup of patients (410).  Another study found that TP53 mutations 
occurred exclusively in MDS (and AML) with an associated del(5q) but not in other 
MDS subtypes (406) which is in line with previous observations in higher-risk MDS (see 
Appendix). Moreover, TP53 mutations and strong p53 protein expression predict for 
shorter survival, higher risk for AML transformation, and a lower CyR in lower-risk 
MDS treated with lenalidomide. We demonstrate that IHC can identify small 
populations of TP53 mutated cells and assessment of p53 protein expression should 
therefore be integrated in the routine diagnostic work- and follow-up of MDS patients. 
Finally, the TP53 mutation status should be included in current risk assessment systems 
of MDS patients.  
 
7.2. Paper III 
The study was closed after enrollment of 28 patients and the approval of azacytidine 
by the EMA as first line treatment for high-risk MDS. The overall response rates in 
this cohort with extremely advanced disease was 20% (3/15) in AML and 36% (4/11) 
in MDS, respectively. All responders completed 16 weeks of treatment. The median 
OS time for the whole cohort was 5.6 months (range, 0.4-30.9+ months), while it was 
19.0 months (range, 4.8-30.9+ months) in responding patients. This response rate was 
encouraging considering the risk profile of the cohort. 
Paraffin blocks were available for 24 patients at inclusion; strong p53 expression was 
seen in 15/24 (62%) patients before treatment start.  The percentage of cells with 
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strong p53 expression was 1-2% in five patients and >10% in the other ten patients. A 
cut-off of 10% was therefore used when comparing IHC results and TP53 mutational 
status. In six of the nine patients who responded to treatment, p53 protein expression 
was absent or low. TP53 mutations were detected in 15 of 24 (62.5%) patients. The 
results of p53 by IHC correlated well with TP53 mutational status: 12/15 patients 
with a mutation had ≥10% p53 staining cells by IHC; two patients had a frame shift 
mutation leading to a premature stop codon and were negative by IHC and one patient 
had a G266V mutation. The TP53 mutational status was significantly associated with 
treatment response (p=0.047).  
In this study, we showed that monotherapy with higher doses of lenalidomide than 
conventionally used for low-risk del(5q) MDS was able to inhibit the del(5q)- clone 
in patients with extremely advanced del(5q) MDS or AML. This indicates that 
lenalidomide given upfront together with azacytidine or induction chemotherapy 
could potentially lead to higher response rates. In a recent phase 1 and subsequent 
phase 2 clinical trial of azacitidine in combination with lenalidomide in patients with 
higher-risk MDS the combination therapy was well-tolerated with sustained therapy 
responses (216, 217).  
Our study is presently followed-up by a multicentre open randomized phase II study 
comparing the efficacy and safety of azacitidine alone or in combination with 
lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a 
karyotype including del(5q) (NMDSG10B study).  
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8.  CONCLUSIONS   
 
• TP53 mutations occur at an early stage in approximately one fifth of lower-risk 
MDS patients with deletion of chromosome arm 5q  
• TP53 mutations are significantly associated with shorter OS, higher AML risk 
and failure to cytogenetic response to lenalidomide 
• Strong p53 protein expression by IHC is an independent prognostic marker and 
associated with poor cytogenetic response but not with transfusion 
independency in patients treated with lenalidomide 
• Strong p53 protein expression is a sensitive biomarker for disease progression 
and cytogenetic evolution and should be integrated in the diagnostic work up 
and follow-up of all lower-risk del(5q) MDS 
• Strong p53 protein expression reflects TP53 mutation while moderate staining 
predominantly reflects wild-type TP53 
• Monotherapy with higher doses of lenalidomide can inhibit the del(5q)- clone 
in advanced MDS or AML and a karyotype involving deletion of 5q  
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9.  FUTURE PERSPECTIVES 
The findings presented in these thesis, in particular the role of TP53 mutations and 
IHC for p53 in lower-risk del(5q) MDS, has already generated significant response 
among clinical hematologists due to their potential impact on current risk 
stratification and choice of treatment for this so called “low-risk” MDS subgroup.  
The survival curve of TP53 mutated patients is comparable to that of INT-2 risk 
MDS, and the question is how TP53 status will influence risk stratification in the 
future. In light of the ongoing discussion regarding the approval of lenalidomide (len) 
by the European Medical Association (EMA), our findings have generated interest 
also outside the clinical setting. Therefore, an Advisory board meeting with experts in 
the field took place in March 2013 in Paris with the aim to further develop strategies 
for validating the role of TP53 mutations and the use of IHC as a biomarker for 
mutations in lower-risk MDS. There was an agreement that TP53 mutations and p53 
IHC are independent prognostic markers for outcome in del(5q) MDS. However, it 
has to be further investigated to what extent this can be used as a basis for clinical 
decision making and choice of optimal therapeutic strategy. To further proceed in this 
effort and to define the role of len in both mutated and unmutated patients, an 
international, multicenter prospective, diagnostic study on behalf of the Advisory 
Board will be conducted with the aim to assess different methods for p53 protein 
detection in correlation with mutational analysis for TP53. 
In addition, the role of wild type TP53 and mutant TP53 as a key regulator of 
hematopoietic stem cell (HSC) behavior in terms of HSC quiescence, self-renewal, 
and apoptosis should be further studied in context of del(5q) MDS. A beneficial effect 
of lenalidomide in patients with 5q- syndrome has been demonstrated in both lower- 
and higher risk del(5q) MDS. However, len does not eradicate the del(5q) stem cells, 
possibly because HSC are typically dormant, arrested by non-p53 dependent 
mechanisms. Moreover, the suggested mechanism of action of lenalidomide in del5q 
MDS may be hampered by the presence of TP53 mutations. Thus, future research 
needs to address therapy resistance or failure in this group of patients; p53 could be a 
potential target in this setting. The use of lenalidomide in del(5q) higher risk MDS 
and AML needs to be further studied and optimized. A combination study with 
chemotherapy is ongoing in the Nordic countries (NMDSG10B clinical trial) 
including the assessment of p53 IHC and mutation status. 
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11.  APPENDIX 
 
Table 6. TP53 mutations and p53 IHC in MDS  
Reference Diagnosis group TP53 mutation p53 IHC Significance 
Jonveaux et 
al, Oncogene 
6, 1991 
MDS 5/151 (3%); 3/5 
patients had 
monosomy 17 
NA TP53 mut associated 
with monosomy 17 
Tsushita et al, 
Br J Haematol 
81, 1992 
RA/RARS 
(18x), RAEB 
(8x), RAEB-
T (5x) 
0% (by Sanger 
technique) 
NA No TP53 mutations 
detected (n=35) 
Ludwig et al, 
Leukemia 6, 
1992 
MDS (n=61) 3/61 (5%), all 
RAEB-subtypes 
NA TP53 mutation 
suggested role in 
leukemogenesis 
Neubauer et 
al, Ann 
Hematol 67, 
1993 
RA (3x), 
RARS (7x), 
RAEB (2x), 
RAEB-T (5) 
0% (by Sanger 
technique) 
NA No TP53 mutations 
detected (n=17) 
Orazi et al, 
Mod Pathol 6, 
1993 
MDS, AML, 
CML 
9/10 IHC-+  had 
complex karyo-
types with 
chrom 5/7 
abnormality 
7/11 
(63%) in 
t-MDS, 
3/4 in t-
AML 
P53 IHC negative in 
CML and controls 
Sugimoto et 
al, Blood 81, 
1993 
MDS (44x), 
AML (6x) 
3/44 (7%) (all 
RAEB); 2/3 had 
chrom 5/7 
abnormality 
NA TP53 mut in RAEB 
subtypes, associated 
with complex 
karyotype 
Kitagawa et al, 
Am J Pathol 
145, 1994 
MDS (51x), 
AML (42x), 
AA (20x) 
NA 7/51 MDS 
(14%) 
IHC+, 
2/42 AML 
(5%) 
IHC negative in AA 
and controls; all 7 
MDS with p53+ at 
diagnosis evolved to 
AML 
Lepelley,  
Leuk 8, 1994 
MDS, AML, 
ALL, CLL 
16/19 IHC+ 
cases showed 
missense 
mutations exon 
4-8 
2/19 
AML, 
2/21 ALL, 
11/48 
MDS, 
4/40 CLL 
IHC and TP53 
mutation concordant 
in 123 of 128 (96%) 
cases 
Preudhomme 
et al, Leuk 8, 
1994 
MDS and 
AML (n=83) 
10/83 (12%) NA   
Wattel et al, 
Blood 84, 1994 
AML, MDS, 
CLL 
16/107 (15%) 
AML, 20/182 
(11%) MDS 
(RAEB 19x, 
CMML 1x), 
9/81 (11%) CLL 
NA TP53 mutation 
associated with 
shorter OS and poor 
therapy response 
Adamson et 
al., Br J 
Haematol 89, 
1995 
RA, RARS, 
CMML, 
RAEB, 
secondary 
AML 
4/26 (15%) 
(RAEBx2, 
MDS-AML 2x) 
NA TP53 mutations 
considered as 
terminal genetic 
event 
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Reference Diagnosis Group TP53 
mutation 
p53 IHC Significance 
Kaneko et al, 
Blood 85, 
1995 
MDS (n=57) 7/57 (12%) 
(RAEB 6x, 
RA 1x); 5/7  
patients had 
del(5q) 
abnormality 
NA TP53 mutations 
detected at an early 
disease stage,  
associated with 
AML risk 
Lai et al, 
Leukemia 9, 
1995 
MDS, AML del(17p) in 
4.3% of 
MDS/AML 
patients 
NA del(17p) highly 
associated with 
TP53 mutations 
Mori et al, 
Leuk Res 19, 
1995 
RA (5x), RAEB 
(3x), CMML (4x), 
RAEB-T (2x), AML 
(12x) 
4/24 (16.7%), 
no mutation 
detected in  
RA subtype 
NA TP53 mutations 
detected at 
diagnosis and 
correlated with 
increased AML risk 
Kikukawa et 
al, Br J 
Haematol 92, 
1996 
Case report: MDS 
type RA with rapid 
progression 
TP53 
mutation 
detected at 
codon 249 
NA TP53 mut in low-
risk MDS patient; 
case report 
including litterature 
review 
Misawa et al, 
Leuk Lymph 
23, 1996 
   Review article on 
TP53 mutations in 
MDS 
Mitani et al, 
Leukemia 
1997 
MDS, MDS-AML 
(total 44x) 
4/44 (9%) 
(RAEB 1x, 
MDS-AML 3x) 
NA TP53 mutations 
associated with 
advanced disease 
Elghetany et 
al, Ann 
Hematol 77, 
1998 
RA (28x), AA 
(10x), normal 
controls (37x) 
NA 19/28 
(67%) RA 
patients 
p53+ 
p53 overexpression 
in RA but not in AA 
or normal controls 
Kikukawa et 
al, Br J 
Haematol 
100, 1998 
RAEB-2 with 
monosomy 17 
Point 
mutation at 
splice donor 
site of intron 5 
NA Rapid disease 
progression and 
resistance to 
chemotherapy 
Misawa et al, 
Leuk Res 22, 
1998 
AML de novo 
(n=31), AML with 
dysplasia (n=17), 
secondary MDS-
AML (n=20),  
t-AML (n=5)  
12/73 (16%) 
(5/12 were 
MDS-AML) 
NA TP53 mutation 
present already at 
diagnosis in 
patients with 
secondary AML 
(MDS) 
Padua et al,  
Leukemia 
12, 1998 
RARS (16x), RA 
(17x), RAEB (10x), 
CMML (32x) 
4/50 (8%) 
(RARS 2x, 
RA, 1x, RAEB 
1x) 
NA TP53 mutation not 
associated with 
increased AML risk 
Soenen et al, 
Leukemia 
12, 1998 
Case report: 
secondary/therapy-
related MDS 
t(15,17), FISH 
del (17p) 
p53 (DO7) 
strong 
protein 
expression 
TP53 mutation 
associated with 
del(17p) in t-MDS 
Tang et al, 
Anticancer 
Res 18, 1998 
 
 
RA 10x, RARS 3x, 
CMML 6x, RAEB 
15x, RAEB-T 9x, 
MDS-AML 4x 
5/47 (11%); 
RAEB 4x, 
MDS-AML 1x) 
4/5 detected 
at diagnosis 
NA TP53 mutation early 
genetic event and 
associated with 
poor survival 
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Reference Diagnosis 
Group 
TP53 
mutation 
p53 IHC Significance 
Horiike et al. , 
Leukemia 13, 
1999 
Therapy-
related MDS 
or AML (21x); 
12/21 with -
5/5q- and/or -
7/7q- 
6/21 (29%)  NA TP53 mutations only 
in patients with 
chromosome 5/7 
abnormalities 
Kanavaros et 
al, Clin Exp 
Pathol  47, 1999 
MDS (30x), 
AML (22x), 
MPN (16x) 
NA 6/30 (20%) 
MDS p53+; 
6/22 (27%) 
AML p53+ 
p53 overexpression 
in myeloid lineage in 
MDS/AML but not in 
MPN or normal BM 
Kikukawa et al, 
Am J Pathol 
155, 1999 
RA, RARS, 
RAEB, 
RAEB-t, 
CMML (total 
52x) 
3/8 (38%) 
with positive 
IHC were 
mutated 
8/52 (15%) 
IHC+ at 
initial 
diagnosis 
IHC associated with 
OS and AML risk: 5/8 
(63%) IHC+ patients 
evolved to AML 
compared with 9/44 
(2%) IHC-negative 
Magalhaes et al, 
Haematologica 
84, 1999 
RA (19x) NA 2/19 p53+ p53 expression 
associated with 
progression  
Kurotaki et al, 
Act Hematol 
102, 2000 
RA (10x), 
RAEB (27x), 
MDS-AML 
(12x), de 
novo AML 
(13x) 
NA IHC for bcl-
2 and p53 
Higher frequency of 
p53 overexpression in 
MDS-AML as 
compared to de novo 
AML 
Elghetany et al. 
Leuk Res 24, 
2000 
RA (28x), AA 
(10x) 
NA Comparison 
of three p53 
MoAbs: p53 
DO7, Pab 
1801, Pab 
240 
All three p53 MoAbs 
negative in AA; 
antibody selection 
has impact on results 
Christiansen et 
al, JCO 19, 2001 
t-MDS (52x), 
t-AML (25x) 
21/77 (27%); 
6/21 del(17p) 
NA Frequent TP53 mut in 
t-MDS/AML, high 
association with 
del(5q) and complex 
karyotype 
Kita-Sasai et al, 
Br J Haematol 
115, 2001 
RA(54x), 
RARS (4), 
RAEB (31x), 
RAEB-T (19), 
CMML (10x) 
16/118 (13%) 
(RA 5x, 
RAEB 8x, 
RAEB-T 3x) 
NA complex karyotype in 
11 of 16 patients with 
TP53 mutation 
Ramos et al, 
Haematologica 
87, 2002 
MDS (n=61), 
AML (n=17), 
controls 
(n=25) 
NA strong p53 
(DO7) 
expression 
seen in 
MDS but 
not normal 
controls 
p53 IHC correlated 
with lower Hb and 
WBC, higher BM blast 
count and OS 
Imamura et al, 
Leukemia 16, 
2002 
RA (n=8), 
RAEB (n=11), 
RAEB-T (2x), 
CMML (2x) 
6/21 (28%), 
RAEB (5x), 
RA (1x) 
NA 5/6 mut+ evolved to 
AML; 5/6 patients had 
chrom 5 and/or 7 
abnormality 
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Reference Diagnosis 
Group 
TP53 
mutation 
p53 IHC Significance 
Fidler et al, 
Haematologica 
89, 2004 
RA (4x), 5q-
(20x), RARS 
(1x), RAEB 
(11x), RAEB-T 
(2x), CMML (1x), 
MDS-AML (1) 
3/40 (7.5%) 
(all RAEB) 
NA No mutation found 
in MDS with 
isolated del(5q) 
Side et al, 
Genes Chrom 
Cancer 39, 
2004 
t-MDS/AML with 
chromosome 5/7 
abnormality 
(n=26) 
5/23 (21%) NA TP53 mutations 
associated with 
chromosome 5/7 
abnormalities 
Zolota et al, 
Pathology Res 
Practice 203, 
2007 
AML (n=42) NA p53 (DO7)  
detected in 
81% of 
cases 
No significant 
correlation 
between p53 IHC 
and outcome 
Iwasaki et al, 
Pathology 
International 
58, 2008 
RA (19x), RARS 
(1x), RAEB 
(13x), RAEB-T 
(3x), CMML (1x), 
MDS-AML (11x) 
7/48 (14%) 
(RA 1x, RAEB 
3x, MDS-AML 
3x); DNA  
from FFPE 
BM sample 
p53 (DO7)  Patients with AA 
were p53 IHC 
negative; TP53 
mutation 
associated with 
strong p53 staining 
Jasek et al, 
Leukemia 24, 
2010 
Cohort of 379 
patients with 
MDS/AML 
 NA TP53 detected in 
75% MDS/AML 
with complex 
karyotypes 
involving chrom 
5/7 
Saito et al, 
Leuk Res 35, 
2011 
Childhood MDS: 
t-MDS (1x), de 
novo MDS (n=6), 
AML with 
dysplasia (n=2), 
JMML (18) 
1/9 patients 
with MDS; no 
TP53 mut in 
JMML patients 
Strong p53  
expression 
<2% in non-
mutated and 
>50% in 
mut+ 
TP53 mutation 
associated with 
resistance to 
chemotherapy 
(one patient) 
Kulasekararaj 
et al, Br J 
Haematol 2012 
MDS (IPSS low-
/high risk MDS) 
and secondary 
AML/t-AML 
(n=318) 
30/318 
(9.4%), 
predominantly 
missense 
mutations 
p53 (DO7); 
73% mut+ 
had strong 
p53 staining 
TP53 mutations 
exclusively in MDS 
with isolated 
del(5q) or complex 
karyotype 
including -5/del(5q) 
Sebaa, et al., 
Genes Chrom 
Cancer 51, 
2012 
MDS (26x) and 
AML (17x) with 
del(5q) 
3/18 (17%) 
low-risk MDS, 
8/15 (53%) 
high-risk 
NA TP53 mutations 
associated with 
shorter OS 
Shih et al, 
Haematologica 
2013 
t-MDS/AML 
(n=38) 
8/38 (21%); 
83% of mut+ 
had del(5q) or 
monosomy 5 
NA TP53 mutations 
associated with 
shorter OS 
NA, not applicable; chrom, chromosome; OS, overall survival; AML, acute myeloid 
leukemia; t-AML, therapy-related AML; AA, aplastic anemia; RA, refractory anemia; 
RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess 
of blasts; CMML, chronic myelomonocytic leukemia; JMML, juvenile myelomonocytic 
leukemia; MPN, myeloproliferative neoplasm; ALL, acute lymphoblastic leukemia; 
CLL, chronic lymphocytic leukemia 
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